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Urokinase (uPA) and urokinase receptor (uPAR) are present in the urinary 
tract of people, mice, rats and cows. The presence of urokinase and urokinase 
receptor in the urinary tract of dogs has not been documented. Documenting the 
presence of uPA and uPAR in the urinary tract of healthy dogs will help 
determine the role these proteins play in pathology of the urinary tract in further 
research. 
  Urine was collected from fifty-four healthy dogs. A fluorescence assay was 
developed using the fluorogenic substrate Z-Gly-Gly-Arg-AMC, HCl. This assay 
documented presence of active uPA-like protein in concentrated urine. A direct 
sandwich ELISA assay was developed using a mouse anti-mouse primary 
antibody and a biotin labeled rabbit anti-human secondary antibody. This ELISA 
documented presence of active and inactive uPA-like protein and measured 
concentration of uPA-like protein in concentrated urine.  
 Tissues from the urinary tract of eleven normal dogs; four intact females, 
five intact males and two castrated males; were collected from kidney, ureter, 
urinary bladder, urethra, prostate and testicle. SDS-PAGE/Western blot analysis 
using mouse anti-mouse, mouse anti-human and rabbit anti-human uPA 
antibodies and a mouse anti-human uPAR antibody were used to identify uPA-
like and uPAR-like protein on the basis of molecular weight and antigen-antibody 
reactions. 
Immunoprecipitation was employed to enhance identification uPA-like and 
uPAR-like protein using mouse anti-mouse, mouse anti-human and rabbit anti-
human uPA antibodies and a mouse anti-human uPAR antibody. 
 xiv
Immunohistochemistry was utilized to identify staining in specific cell types within 
the urinary tract. The uPA antibodies used were directed against human and 
mouse urokinase. The uPAR antibody used was directed against human 
urokinase receptor. 
A urokinase-like protein is present in urine from healthy dogs in small but 
measurable quantities. Urokinase-like and urokinase receptor-like protein are 
present in the urinary tract of the healthy dog. This distribution is similar to that 
identified in people. The role of urokinase-like and urokinase receptor-like protein 
in the urinary tract of the normal dog is yet to be defined.  
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Chapter 1 Introduction 
 
1.1 Urinary Tract Surgery in Animals 
Urinary tract surgery is performed in dogs to relieve urinary tract 
obstruction due to neoplasia or urolithiasis, to correct congenital abnormalities or 
to obtain biopsies.  Surgical procedures include cystotomy, cystostomy, partial 
cystectomy, nephrectomy, nephrotomy, ureteral implantation, urethrostomy and 
urethrotomy. Post-operative hemorrhage is a potential complication of urinary 
tract surgery, particularly following renal or lower urinary tract diversion surgery. 
In some cases, post-operative hemorrhage may necessitate blood transfusion 
and lead to extended hospitalization.1, 2 
1.2 Factors Contributing to Post-Operative Urinary Tract Hemorrhage 
 Factors contributing to post-operative hemorrhage include: the vascularity 
of penile tissue, continued mechanical disruption of blood clots due to urine flow 
past the surgical site, and failure to achieve an adequate fibrin seal when the 
urethrostomy is left to heal by  second intention healing of urethrotomy closes 
and the selected suture pattern for urethrostomy closures.2, 3 
1.3 The Role of the Fibrinolytic System after Urinary Tract Surgery 
The role of the fibrinolytic system in dogs after urinary tract surgery has 
not been established. Some have alluded to the role of urokinase in excessive 
post-operative hemorrhage after urethral surgery.2   
1.4 Urokinase and Urokinase Receptor in the Urinary Tract 
Urokinase or urokinase plasminogen activator (uPA) and urokinase 
receptor or urokinase plasminogen activator receptor (uPAR) are present in the 
tissues of the mammalian urinary tract. 4-6 The function of uPA and uPAR in the 
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urinary tract is not completely understood but they are important in development 
of the tubular anatomy of the urinary tract and in maintaining patency within the 
developing and mature urinary tract.7  
The proteolytic activity of human urine and its ability to dissolve fibrin clots 
has been known for decades and was discovered to be due to the presence of a 
plasminogen activator, later named urokinase.5, 8, 9 Urokinase is known to be 
increased in inflammatory and other pathological conditions of the urinary tract in 
people.7, 10, 11 Quantification of uPA in canine urine and identification of urokinase 
and urokinase receptor in tissues of the urinary  tract may help in determining if 
they have a role in fibrinolysis which may contribute to post operative 
hemorrhage following urinary tract surgery in dogs. 11, 12 
1.5 Clinical Significance in Dogs 
Post-operative hemorrhage in dogs undergoing urinary tract surgery can 
be substantial. Whether uPA has a substantial role in prolonged bleeding after 
urinary tract surgery in dogs is unknown. If urokinase does play a significant role, 
use of drugs such as ε-aminocaproic acid that competitively inhibit plasminogen 
activator substances may be useful. ε-aminocaproic acid has been successfully 
used in people to inhibit uPA and decrease bleeding during renal amyliodosis 
and menstruation.13, 14 Anecdotal reports of ε-aminocaproic acid successfully 
halting hemorrhage within the urinary tract are exist in veterinary medicine, 
however, no controlled studies have been performed.15 Dosages of ε-
aminocaproic acid have not been established for dogs.15  
The function of uPA within the urinary tract of dogs is not known but might 
be important in maintaining patency of the urinary tract in the face of hemorrhage 
 3
and in the embryologic development of the urinary tract, which is a complex 
system of hollow tubes. Identifying and quantifying uPA and uPAR in the normal 
canine urinary tract is an initial step in evaluating a possible role of uPA in the 
fibrinolytic system of the normal canine urinary tract. A description of the 
distribution of uPA and uPAR in urinary tract of normal dogs is the first step in the 
identification of disease related changes in the distribution of uPA and uPAR.  
1.6 Investigational Objectives 
The objectives in this investigation were: 
1. To identify and quantitate urokinase in the urine of healthy dogs. 
2. To identify urokinase and urokinase receptor in the urinary tract of 
healthy dogs. 
3. To validate the use of antibodies directed against human uPA and 
uPAR and mouse uPA for identification of uPA and uPAR in the urinary 
tract of healthy dogs. 
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Chapter 2 Literature Review 
 
2.1 Introduction 
 The focus of this thesis is on the distribution of urokinase and urokinase 
receptor in the urinary tract of the normal dog. These proteins play an important 
role in the activation of the fibrinolytic system in the body, a system that is 
integrally involved in hemostasis.  
2.2 Hemostasis 
 Hemostasis refers to the prevention of blood loss through a vessel when 
vascular integrity is lost. Hemostasis is achieved as the result of several integral 
mechanisms. These mechanisms include vascular spasm, formation of a platelet 
plug, formation of a blood clot as a result of blood coagulation, and formation of a 
permanent seal through a fibrin plug.1 The final step in those vessels which are 
able to restore patency is clot lysis.2 
 2.2.1 Vascular Constriction 
 
 Following trauma to a blood vessel, the autonomic nervous system, 
myogenic spasm and humoral factors released from traumatized endothelium 
combine together to reduce the flow of blood from the vessel. The majority of the 
vasoconstriction is attributed to myogenic contraction. In very small vessels 
platelet derived thromboxane A2 is responsible for most of the constriction.1, 2 
Endothelin and bradykinin also contributes to vascular constriction.2 
 2.2.2 Platelet Plug Formation 
 
 Small holes within blood vessels are sealed with a platelet plug as 
opposed to a blood clot. Platelets have many functional characteristics that allow 
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them to contribute to hemostasis. Actin, myosin and thrombosthenin allow 
platelets to contract and expand. Remnants of endoplasmic reticulum and Golgi 
apparatus mediate synthesis of enzymes and storage of calcium for contraction 
and expansion. Platelets are capable of producing adenosine triphosphate (ATP) 
and adenosine diphosphate (ADP) within mitochondria for energy for platelet 
activity. Prostaglandins are synthesized within platelets. These prostaglandins 
contribute to local vascular and tissue reactions like inflammation. Platelets 
contain fibrin-stabilizing factor which is important in creating bonds and cross-
linkages between fibrin molecules and fibers. Platelets also secrete growth factor 
that causes vascular endothelial, smooth muscle and fibroblasts to multiply and 
grow, allowing vascular repair. Platelet surfaces contain glycoproteins that 
promote adhesion to injured endothelial cells and exposed vessel wall. Platelet 
membranes also contains phospholipids that participate throughout the clotting 
process 1 
 In the presence of vascular injury platelets undergo three reactions: 1. 
Adhesion and shape change, 2. secretion, and 3. aggregation. Reactions occur 
simultaneously. Following adhesion, contractile proteins cause release of 
granules from the platelets that adhere to collagen in the vessel wall and von 
Willebrand factor in the plasma. Platelets secrete adenosine phosphate (ADP) 
and thromboxane A2 which activate and recruit more platelets to the forming 
plug.1, 2 Prostaglandin I2 is secreted by surrounding intact vascular endothelium 
inhibiting platelet aggregation past the site of injury by decreasing release of ADP 
from extra platelets. The platelet cell membrane glycoprotein also inhibits 
adherence to normal endothelium.2 
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 2.2.3 Blood Coagulation and Fibrin Plug Formation 
 
 If the injury to a vessel is severe a blood clot will begin to form in 15 to 20 
seconds. If the trauma has been minor, formation of this clot may take 1 to 2 
minutes. The process is initiated by activated substances from the endothelium 
and exposed collagen, platelets and blood proteins adhering to the vessel wall. 
The clot can completely fill the end of a small vessel and within an hour begins to 
retract.1 
 Fibrin plug formation occurs when the blood clot is invaded by fibroblasts, 
creating connective tissue throughout the clot. This process begins within a few 
hours of the blood clot formation and continues into organization of fibrous tissue 
over 1 to 2 weeks.1  
 2.2.4 Clot Lysis 
 
 Clot lysis requires the activation of circulating plasminogen to plasmin. In 
the initial stages of clot formation, plasminogen is trapped within the clot.  Tissue 
plasminogen activator is then released, which cleaves the plasminogen to 
plasmin, allowing the clot to be removed.2, 3 In non-vascular tissues a similar 
process is occurring. However, in non-vascular tissues urokinase is the 
plasminogen activator which cleaves the plasminogen.3  
2.3 The Coagulation System 
 The coagulation system is composed of more than a dozen factors which 
interact in a complex cascade of reactions within blood vessels and in the 
surrounding tissues to produce hemostasis (table 2.1 and figure 2.1). Most of the 
numbered factors are circulating inactive serine proteases, except factors V and 
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VIII and fibrinogen which are labile. The factors become activated after initiation 
of coagulation. The coagulation pathway is divided into the intrinsic or contact 
pathway, the extrinsic pathway and the common pathway.2, 4  Plasma in dogs 
and people have similar activity of prothrombin. Dogs have higher concentrations 
and activities of fibrinogen, factor VIII and contact factors (factor XII, prekallikrein, 
high-molecular-weight-kininogen and factor IX).4, 5 
Table 2.1. Coagulation Factors 
Name Synonym Pathway 
Factor I Fibrinogen Common 
Factor II Prothrombin Common 
Factor III Tissue factor; tissue 
thromboplastin 
Extrinsic 
Factor IV Calcium All 
Factor V Proaccelerin; labile factor Intrinsic/extrinsic 
Factor VII Proconvertin; stabile factor Intrinsic 
Factor VIII Antihemophilac factor A Intrinsic/common 
Factor IX Christmas factor; 
antihemophilic factor B 
Intrinsic 
Factor X Stuart factor Common 
Factor XI Plasma thromboplastin 
antecedent 
Intrinsic 
Factor XII Hageman factor Intrinsic 
Factor XIII Fibrin-stabilizing factor Common 
Prekallikrein Fletcher factor Extrinsic 
High-molecular-weight-
kininogen 
Fitzgerald factor, HMWK  Intrinsic/extrinsic 
Platelets  Intrinsic/extrinsic 
Kallikrein  Intrinsic 
Protein C  Intrinsic/common 
Protein S  Common 
 
2.3.1 The Extrinsic Pathway 
 
 The extrinsic pathway is activated when traumatized tissue in vascular 
 
adventitia and surrounding tissues, i.e. muscle, release tissue factor (TF) from 
 
the cell membranes. Tissue factor complexes with circulating blood coagulation 
 
factor VII in the presence of calcium and phospholipids.2, 4 Factor VII is activated 
 
by factors Xa and IXa or by factor XIIa. The factor VIIa-TF complex then  
 








Factor VII Factor VIIa
Ca 2+, Phospholipids
























Ca 2+, Factor VIIIa, 
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Figure 2.1. Coagulation Pathway: Blue arrows represent activation, Green broken arrows 
represent inhibitors, Red dotted arrow represents upregulation. 
 
complexes with tissue and platelet phospholipids, to form prothrombin activator.  
Prothrombin activator splits prothrombin to thrombin. At this point factor V can 
also split prothrombin to thrombin and thrombin itself can cause prothrombin to 
split into active thrombin in the intrinsic cascade.2 
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 2.3.2 The Intrinsic Pathway 
 
 The intrinsic pathway is initiated by trauma to the blood vessel itself when 
collagen in a damaged vessel wall is exposed. This trauma causes activation of 
factor XII and release of platelet phospholipids.2 Factor XII complexes with factor 
XI and high-molecular-weight-kininogen (HMWK), causing activation of factor XII. 
Factor XIIa activates factor XI and prekallikrein. Kallikrein increases factor XII 
activation. High-molecular-weight-kininogen binds to prekallikrein and factor XI 
as a cofactor for the intrinsic pathway surface-mediated reactions.4 Factor IXa 
combines with factor VIII in the presence of platelet phospholipids to activate 
factor X.2  
 The complement system acts with the contact phase of blood coagulation. 
The complement system is comprised of plasma proteins which give rise to 
chemotaxis mediators, increased vascular permeability, opsonin activity, 
phagocytic activity and cytolysis. Factor XIIa fragments initiate the classical 
pathway of complement by activating C1.6  
 2.3.3 The Common Pathway 
 
 The result of both the intrinsic and extrinsic pathways is the conversion of 
factor X to factor Xa. This is the starting point of the common pathway or the 
phase of thrombus formation. Thrombin cleaves fibrinogen into fibrin monomers. 
The initial clot is not cross-linked and is quite weak. Thrombin activates factor 
XIII, present in plasma and platelets. Factor XIIIa then creates fibrin dimers by 
cross-linking adjacent fibrin fibers. This gives the clot strength and durability.2, 4 
Fibrinogen is an important protein in both the formation and lysis of blood 
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clots. Fibrinogen is produced by hepatocytes and megakaryocytes and circulates 
in the plasma. Fibrinogen is a symmetrical dimer which is cleaved by Factor IIa to 
convert fibrinogen to fibrin. Once fibrin is formed it stacks with platelets and 
thrombin to form a loose fibrin plug. The fibrin molecules are later cross-linked by 
factor XIII to form a stable fibrin plug. This is where the fibrinolytic system begins 
to dissolve the plug.  
2.4 The Fibrinolytic System  
 Until the 1990’s the fibrinolytic system was regarded as being primarily 
involved in the regulation of intravascular clot dissolution via activation of 
plasminogen. This came from the knowledge that impairments in the fibrinolytic 
system resulted in increased bleeding or thromboembolic disease. In more 
recent research with knock-out mice it became evident that the fibrinolytic system 
has a more global role in the body. Fibrinolysis is involved in many aspects of 
cellular activity and tissue development, both beneficial and harmful to an 
organism as well as thrombolysis.7 Some authors consider this system to be 
more properly named the plasminogen system due to the role in many other 
activities besides just resolution of fibrin clots within the vascular system.3 
The fibrinolytic system has many components (table 2.2). The role of the 
fibrinolytic system in mammals is the maintenance of patent vasculature during 
thrombosis. It also functions during the inflammatory and maturation phases of 
wound healing. Fibrinolysis occurs for in the testicle and the placenta. 
Fibrinolysis is also important in angiogenesis, embryologic development, tissue 
remodeling, and in the pathogenesis of neoplastic disease. 8-18 
Tissue plasminogen activator (tPA) and urokinase (uPA) are the most 
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Table 2.2 Components of the Fibrinolytic System 





Plasminogen 92 0.2 mg/ml 50 h Proenzyme 
Tissue-type 
plasminogen activator 
70 5-10 ng/ml 2-3 min Plasminogen 
activator 
Urokinase 53, 33 1 ng/ml 3-5 min Plasminogen 
activator 
Prekallikrein 88 0.04 mg/ml 25 h Proenzyme 
Factor XII 80 0.03 mg/ml 60 h Proenzyme 
α2-Antiplasmin 70 0.07 mg/ml 50 h Plasmin inhibitor 
α2-Macroglobulin 4  160   Protease inhibitor 
Plasminogen activator 
inhibitor type-1 




70   Inhibitor of uPA and 
two-chain tPA 





75   Plasminogen 
binding 
Thrombin activated 
inhibitor of fibrinolysis 
49   Attenuation of fibrin 
cofactor activity 
 
important mediators of plasminogen activation. The tPA mediated pathway is 
primarily involved in the dissolution of blood clots within the vascular system. The 
uPA-mediated pathway is activated to provide fibrinolysis for events including cell 
migration, tissue remodeling and fibrosis formation. Outside of the vascular 
system inhibitors of the fibrinolytic system balance the action of fibrinolysis and 
include α2 antiplasmin, α2 macroglobulin, antithrombin III, α2 antitripsin, C2  
inactivators, plasminogen activator inhibitor 1 (PAI 1) and plasminogen activator 
inhibitor 2 (PAI 2).9, 19 
Fibrinolytic activity in the blood is mediated by plasma and cellular 
components. In people and dogs, the plasma fraction contributes approximately 
30% of the fibrinolytic activity.20 Urokinase, tPA and PAI-1 and PAI-2 are not 
detectable in plasma of healthy people.21 However, these enzymes are present in 
normal circulating monocytes.21  Mononuclear phagocytes express uPA, uPAR 
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and plasminogen activator inhibitor (PAI).22, 23 Neutrophils and platelets have 
high density of uPAR in their membrane. The urokinase receptors bind uPA and 
accelerate plasminogen activation and fibrinolysis.24-26 Cytokines such as 
interferon gamma and tumor necrosis factor stimulate plasminogen activator (PA) 
and PAI activity in monocytes.23   
 The plasma kinin-forming system consists of three plasma proteins that 
interact with certain negatively charged surfaces or macromolecular complexes. 
They participate in the contact phase of the intrinsic coagulation pathway to 
induce fibrinolysis. 9, 27-30  The three plasma proteins are high molecular weight 
kininogen (HK), coagulation factor XII (FXII), and prekallikrein.29 Factor XII 
activation is induced by several mechanisms. Collagen contact and negatively 
charged surface contact, HMWK (Fitzgerald factor) and Kallikrein (Fletcher 
factor). Plasmin itself also activates Factor XII leading to fibrinolytic amplification. 
9, 28 For optimal activation of Factor XII (Hageman factor) both HK and 
prekallikrein must be present to participate in the contact phase of the intrinsic 
coagulation pathway and help induce fibrinolysis. 9, 28 High molecular weight 
kininogen binds to uPAR on the endothelial cell surface.29, 31  Some investigators 
propose that high concentrations of these activators are in circulation for the 
purpose of fibrinolysis.32 Others propose that the circulating concentrations are 
low unless triggered by a thrombolytic event.9 
2.5 Tissue Plasminogen Activator 
 
Tissue plasminogen activator is one of the endogenous extrinsic plasminogen 





























Figure 2.2 Fibrinolytic Cascade:  Blue arrows represent activation, red arrows represent 
inactivation 
 
and is of primary importance for the lysis of clots in the circulatory system.7 It is a 
serine protease with a molecular weight of approximately 70kDa. It is secreted as 
a single chain glycoprotein. The proform has some intrinsic activity; however, the 
two chain form (held by single disulfide bonds) that is produced after cleavage by 
plasmin is the most active form. 28 
Tissue plasminogen activator is produced by endothelial cells, human 
keratinocytes, melanocytes and neurons. It is also produced in numerous human 
neoplastic cell lines such as melanoma, neuroblastoma, ovarian, breast and 
pancreatic cancer.8-11, 13, 14, 16   Tissue plasminogen activator is most active within 
the vasculature and has a high affinity for fibrin or fibrin-bound plasminogen. 
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Tissue plasminogen activator has increased activity in the presence of fibrin 
which leads to localization of activity within a clot, enhanced fibrinolysis and 
improved binding of plasminogen to fibrin clots.33 This all ensures continuous 
plasminogen concentration during tPA-mediated thrombolysis. 9, 28 
Tissue plasminogen activator bound to plasminogen activator inhibitor is 
cleared from the circulation by hepatocytes endocytosis. This clearance is via 
endocytosis. There are no cell surface receptors identified for tPA. 9, 28 
2.6 Urokinase 
 
The fibrinolytic activity of urokinase was discovered decades ago upon the 
discovery that urine could dissolve blood clots.34 Urokinase is a chymotrypsin-like 
serine protease and is the second of two endogenous extrinsic plasminogen 
activators that are important in the conversion of circulating proenzyme 
plasminogen into the active serine protease plasmin in the extravascular 
tissues.7, 35 Urokinase promotes fibrinolysis by catalyzing the cleavage of 
plasminogen to plasmin.36  
Urokinase is a single-chain glycoprotein with a molecular weight of 53 
kDa.28 The chemical structure of uPA is complex. It is composed of three 
domains with 411 amino acids.37 The N-terminal domain (amino acids 9-45) or 
light chain (scuPA) has a growth factor domain. This is called the amino terminal 
fragment and is also known as CD87.38-40 This fragment is the region responsible 
for urokinase receptor binding.41 The kringle domain (amino acids 46-143) 
contains a sequence that interacts with PAI-1. Urokinase also binds to heparin by 
this domain.37 The C-terminal catalytic domain (amino acids 144-411) is the B-
chain or heavy chain.  It has a carboxyl-terminal region with a serine protease 
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domain.37 The two chains are linked by a peptide.  Together they form active uPA 
which is also called high molecular weight urokinase.28, 36  Both single and two-
chain forms of uPA bind to uPAR or low-density lipoprotein (LDL) receptors on 
cell surface membranes.37 The C-terminal domain binds to plasminogen leading 
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Figure 2.3 Urokinase and its cleavage products 
In the mouse and human uPA is produced by many cell types within the 
body but is produced in the greatest quantity by renal epithelial cells of the 
proximal and distal kidney tubules. 42-44 Urokinase is also synthesized in 
glomerular visceral epithelial cells44, 45 and is known to be excreted in mammalian 
urine.46-49 Urokinase is present in human urine in a 1:1 ratio with a uPA 
inhibitor.47 The role of uPA within the urinary tract may be to ensure patency of in 
the face of hemorrhage.49 Urokinase is also present  in the human prostate and 
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semen where it is believed to play a role in sperm motility and maturation, and in 
the urothelium of the bovine urinary bladder.10, 11, 46, 50   
2.7 Urokinase Receptor 
 
Urokinase receptor is a membrane bound protein that binds uPA localizing 
extracellular and basement membrane degradation that promotes cellular 
migration and invasion (figure 2.4).51 Urokinase receptor is a 55-60 kDa 
glycoprotein.52-54  Urokinase receptor is anchored to the plasma membrane of 
cells by a glycosylphosphatidylinositol (GPI) lipid moiety or a GPI tail.40, 51, 55, 56  
Urokinase receptor consists of three different domains: the uPA binding domain 1 
(D1), the connecting domain 2 (D2) and the cell anchoring domain 3 (D3).55  The 
presence of urokinase receptors (uPAR) located on cell surface membranes is 
important, but not essential, for the activity of uPA within the tissues.37  
Urokinase receptor binds both the inactive and active forms of uPA. 40 
Once bound, the inactive form of urokinase becomes activated. Bound active 
urokinase enzyme retains its enzymatic activity. These uPAR are upregulated in 
several neoplastic cell lines and in inflammatory processes on neutrophil 
membranes.26 Although uPAR is present in normal cells, upregulation leads to 
the detrimental effects which have linked urokinase to tumor invasion in breast 
cancer57 and inflammation. Urokinase-uPAR complexes on any cell surface have 
proteolytic, cell migratory, adhesive and chemotactic effects and uPA-uPAR 
participates in extravascular fibrinolysis.55 Extracellular matrix disruption occurs 
because uPAR has high affinity for the extra-cellular matrix protein vitronectin.37  
Urokinase receptor plays a role in invasion and migration of certain immune cells  
including natural killer (NK) cells.51  Increased concentrations of uPA and uPAR 
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have been shown to be associated with a poor prognosis for some cancer lines. 
8-11, 13, 14, 16  In several studies increased plasma concentrations of uPAR have 
been reported in patients with chronic myeloproliferative and neoplastic 
diseases.58  
 
Figure 2.4 Schematic representation of the relationship between uPA and uPAR. G, growth 
factor-like domain; K, kringle domain; C, catalytic domain; D1, uPA binding domain of uPAR; D2, 
connecting domain; D3, cell anchoring domain; PAI-1, plasminogen activator inhibitor-1. 
 
Urokinase receptor facilitates clearance of uPA by cells. The receptor 
bound uPA complexes with PAI-1 and is immediately internalized. The uPA is 
degraded in the lysosomes.37 The LDL receptor family consists of α2-
macroglobulin receptors and very low-density lipoprotein receptor related protein. 
All are located within the cell membrane. These receptors aid internalization of 
the uPA/UPAR/PAI-1 complex through clatherin-coated pits in cell membranes. 
Internalized uPAR is recycled to the cell surface to rebind with another uPA 
molecule.28, 37  Urokinase and urokinase degradation products bind directly to the 
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LDL receptor-relative protein/α2-macroglobulin receptor and are internalized for 
degradation.37 
Urokinase and uPAR have been localized in almost all cell types including 
renal tubular epithelial cells, urothelium, granulocytes and macrophages, 
fibroblast-like and vascular endothelial-like cells in rat tendon, human pulmonary 
alveolar cells, umbilical vein endothelial cells and foreskin cells.59-62 
2.8 Plasminogen and Plasmin 
 
Plasminogen is a single chain glycoprotein with a molecular weight of 92 
kDa. The molecule has five kringle-like domains that contain lysine binding sites 
and C terminal domains. The kringle domains bind to fibrin, cell surfaces and 
plasma inhibitor α2 antiplasmin.7 The kringle domains mediate the interactions of 
plasminogen and plasmin with substrate inhibitors and cell membranes. 
Plasminogen is a circulating zymogen present in all vasculature and body 
tissues. Plasminogen is synthesized in the hepatocytes of mammals and is 
eliminated primarily by catabolic degradation in the plasma.7 63 Secondary 
elimination is accomplished by conversion of the plasminogen to plasmin in 
areas of coagulation and clot formation.9, 28  Plasminogen is also synthesized by 
the seminiferous tubules of the testis in the rat.63 
Plasminogen is cleaved at the Arg561-Val562 bond into the two chain form of 
plasmin.64 The N-terminal heavy (A) chain has effector sites that are lysine 
binding sites. The light (B) chain has an active site homologous with other serine 
proteases (thrombin, Factor Xa) that cleaves lysine-arginine bonds. The light 
chain site allows plasmin to attack any peptide containing an arginine-lysine 
residue like the C-terminal residues on the surface of fibrin.28, 65 These 
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interactions are important for the activity of plasminogen and the localization of 
proteolytic activity of plasmin.7  Plasmin also has the ability to cleave 
plasminogen into lysine plasminogen that has a 20 times increased affinity for 
fibrin.65 This conversions leads to increased reactivity with plasminogen 
activators accelerates conversion of plasminogen to plasmin.9, 28 
Plasmin inactivates elements of the coagulation cascade. Plasminogen is 
present within a fibrin clot bound to fibrin. It is cleaved to plasmin by tPA, uPA or 
kallikrein. Plasmin degrades fibrin into D-dimers and fibrin degradation products 
(FDP’s).25  Plasmin inactivates Factor VIII, V and XII, this aids in lysis of the clot 
by destroying these coagulation factors.1 Plasmin also degrades prekallikrein, 
high molecular weight kallikrein and converts C3 to C3a in the complement 
cascade. 9, 28 
When a clot is formed inside a vessel, the plasminogen is trapped inside 
the clot. The plasminogen does not become plasmin and begin clot lysis until it is 
activated. Tissue plasminogen activator is released from the vascular 
endothelium a day or so after the clot has stopped the bleeding. This results in 
lysis of the clot via plasmin mediated fibrin breakdown. 
Plasmin formation through the action of plasminogen activators is crucial 
for inflammation and wound healing.23, 66  Granulocytes and monocytes are both 
sources of plasminogen activator activity among leukocytes.23, 66  As cells are 
attached to a site of wound inflammation, neutrophils use uPA bound to uPAR to 
concentrate plasmin activity in the targeted tissue. By mobilizing proteolytic 
degradation of fibrin rich blood clots, uPA bound to uPAR and leukocyte integrin 
αMβ2, a membrane bound leukocyte integrin, influences neutrophil adhesion and 
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Figure 2.5 Plasminogen and Plasmin. Glu-Plasminogen is the form secreted by the liver. The 
kringle domains mediate interactions of plasminogen and plasmin with substrates, inhibitors and 
cell membranes and are crucial for the activation of plasminogen and localization of the activity of 
plasmin. Release of the N-terminal domain or PAP forms Lys-plasminogen which can be 
activated in the absence of fibrin at a rate higher than Glu-plasminogen. The N-terminal heavy A-
chain contains all the kringle domains. The C-terminal light B-chain contains the catalytic sites. 
The specificity of plasmin comes from the domains of its heavy chain 
 
migration.25 This allows degradation of the provisional extracellular matrix by 
binding to vitronectin and permits migration of the neutrophils and macrophages 
through the tissue planes. 23, 67, 68  Plasmin is important in all tissue remodeling in 
the face of wound healing because of degradation of fibrin-vitronectin matrices 
and the glycoprotein constituents of basement membranes.66 
Lysine analogs such as ∋-aminocaproic acid bind to lysine binding on the 
N-terminal heavy chain  of plasmin and compete with lysine-like sites of fibrin for 
plasminogen. By binding of plasmin on fibrin they reduce fibrinolysis.69, 70 
2.9 Endogenous Inhibitors of Fibrinolysis 
 
Endogenous inhibitors of fibrinolysis are important in keeping the 
fibrinolytic system in check. Interestingly, most of the activators of fibrinolysis are 
inactive in the absence of the inhibitors. 
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2.9.1 Inhibitors of Plasminogen and Plasmin 
 
The primary inhibitor of plasmin and plasminogen is α2-antiplasmin (α2-
AP), which is located circulating in plasma and platelets. α2-Antiplasmin  is 
secreted by the liver as a 70 kDa glycoprotein.7 Alpha2-AP is important in 
regulation of lysis of the fibrin matrix of a thrombus, providing intermittent 
activation at local sites of fibrin deposition without initiating a systemic proteolytic 
state.7, 28 The α2-AP is bound to fibrin at the C-terminal region, which is the first 
site on fibrin to be degraded by plasmin. It reacts quickly with plasmin, forming an 
irreversible bond at the lysine binding sites. The α2-AP is then partially degraded 
by plasmin. The α2-AP works quickly when plasmin is in circulation. However, 
when plasmin or plasminogen are bound to a cell surface, the lysine binding sites 
are occupied and α2-AP acts more slowly as the plasmin is protected against α2-
AP inactiavtion.28, 65 Fibrin clots are reduced in size layer by layer to provide 
temporary ability at sites of vascular injury.7 
Alpha2-macroglobulin (α2-MG) is a 725 kDa glycoprotein which is also a 
plasmin inhibitor but is only important if α2-AP capacity is exceeded by excess 
circulating plasmin. The α2-MG can only inhibit circulating plasmin and is 
ineffective against cell bound plasmin.9, 28 Alpha2-macroglobulin works at a much 
slower rate than α2-AP. 
Thrombin-activated fibrinolysis inhibitor (TAFI) is a newly identified 
inhibitor which is secreted by the liver as a single chain 58 kDa glycoprotein. Its 
antifibrinolytic activity consists of removing the C-terminal binding sites for 
plasminogen and tPA which are present on the degraded fibrin surface.65 The 
TAFI is activated by thrombin or plasmin.7 This system appears to operate on a 
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threshold system by acting as the means of removing the C-terminal arginine-
lysine groups from the surface of the degraded fibrin. In doing so the α2-AP which 
binds to this site is decreased and the rate of plasmin formation is decreased 
since plasminogen binds to the arginine-lysine sites.65 
Other direct plasminogen and plasmin inhibitors include antithrombin III, 
α2-antitrypsin and C2-inactivators. These inhibitors have some activity in vitro but 
limited activity in plasma.28 
2.9.2 Inhibitors of Plasminogen Activators 
 
Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 
(PAI-2) are important inhibitors of tPA and uPA. Plasminogen activator inhibitor 1 
and PAI-2 are present in low concentrations in plasma. The concentrations are 
increased during neoplasia, sepsis and inflammation. The PAIs are secreted in 
response to thrombin, endotoxin, tumor necrosis factor (TNF) and interleukin-1 
(IL-1). Increased concentrations of PAI-1 have been used as a negative 
prognostic marker in certain cancers in people. 9, 28 
The PAI-1 is synthesized by endothelial cells, hepatocytes and is stored in 
the α granules of platelets. When platelets are activated, they release PAI-1, 
increasing the local concentration of PAI-1 at a clot and therefore increasing the 
proteolytic stability of fibrin matrix.7 The PAI-1 rapidly inactivates tPA by forming 
a reversible complex. The activity of PAI-1 is decreased by activated protein C 
increasing fibrinolysis.9  
Plasminogen activator inhibitor-1 also forms a reversible complex with 
single chain uPA and tPA and inhibits receptor bound uPA and tPA from causing 
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plasminogen activation. Plasminogen activator inhibitor-1 forms a 1:1 complex 
with tPA and uPA. Plasminogen activator-1 is present in plasma and other 
biological fluids in an active and latent form. The active form does not require any 
conformational change to produce its effect. Active PAI-1 can be spontaneously 
reverted to latent PAI-1.  Latent PAI-1 can be activated by phosphatidylinositol 
which is present in phospholipids vesicles from cell membranes. The active PAI-
1 interacts with vitronectin, stabilizing the active PAI-1 and decreasing binding of 
vitronectin to cellular receptors such as those for uPA and tPA.7 
Plasminogen activator inhibitor-2 is expressed by placenta, monocytes 
and macrophages. Plasminogen activator inhibitor-2 inhibits uPA very rapidly but 
inhibits tPA very slowly. 9, 28 
2.10 Fibrinolysis and the Dog 
Dogs have a very potent fibrinolytic system compared to people, 
particularly during pulmonary thromboembolism.71, 72   In one study, a single 
induced pulmonary embolus remained in the pulmonary vasculature of a dog for 
5 days.71 In people with a similar lesion, resolution is usually incomplete even 
after one year.71 The difference may be because canine platelets reveal 
plasminogen activator, tPA and uPA, and plasminogen activator inhibitor-1 
activity, where as human platelets exhibit primarily PAI-1 activity. Endothelial 
cells in the dog also secrete uPA and likely play a role in the breakdown of clots 
in the pulmonary vasculature. Concentrations of uPA in the membranes of canine 
platelets have been shown to be approximately 50 times greater than in 
membranes of human platelets. 71 This difference may play an important role in 
the lack of problems in veterinary patients with deep vein thrombosis and 
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pulmonary thromboembolism compared to similar diseases, injuries and degrees 
of immobility in people.  
2.11 Urokinase and Urokinase Receptor in the Kidney 
High concentrations of urokinase are synthesized in the kidney.40 In 
particular synthesis of uPA is evident in the medullary rays and epithelial cells of 
the proximal and distal kidney tubules in the mouse and human. 42-44 Urokinase 
is also synthesized and bound in human glomerular visceral epithelial cells in 
culture.44, 45 Urokinase and urokinase receptor appear to be very important in the 
pathophysiology of many renal diseases.  
Glomerulosclerosis causes progressive glomerular injury in people due to 
an accumulation of extracellular matrix in the glomerular mesangium. This is a 
common problem in diabetic nephropathy in people and has been shown in rats 
and mice as well.73, 74 Glomerular mesangial cells are a major source of 
extracellular matrix production in chronic glomerular disease and cultured 
mesangial cells produce uPA, tPA and PAI-1. 75, 76  Since abnormal extracellular 
matrix accumulation is often preceded or combined with an increased expression 
of extracellular matrix degrading enzymes77,  PAI-1 has been implicated as a 
mediator of extracellular matrix accumulation in renal disease.78  In cultured 
human mesangial cells, low-density-lipoprotein (LDL) appears to upregulate PAI-
1 synthesis and activity, and uPA and tPA after long term incubation in biphasic 
patterns. Upregulation of PAI-1, uPA and tPA may be mediated by delayed 
protein kinase C activation associated with increased PAI activity. Protein kinase 
C is activated by diacylglycerol (DAG), a product of phosphatidylinositol. 
Phosphatidylinositol turnover is stimulated by oxidized LDL in culture. In vivo this 
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may favor an accumulation of matrix within the kidney leading to 
glomerulosclerosis.79 
Renal ischemia and reperfusion injury is mediated by plasminogen 
activators as well as the previously described free radicals, leukocytes, cytokines 
proteinases.80, 81 Renal ischemia/reperfusion injury is often encountered in 
surgery particularly during procedures involving the vasculature or 
transplantation.80  In a rabbit model of renal ischemia/reperfusion the expression 
of uPA and tPA was down-regulated and PAI-1 was up-regulated in cell lysates 
of the ischemic kidney compared to the non-ischemic kidney. Fibrinolytic activity 
was also lower in the ischemic kidney than the non-ischemic kidney. Repression 
of fibrinolysis may contribute to the progression of renal damage in this model. 80  
In immune mediated nephritis or nephrotoxic nephritis, fibrin deposition, 
glomerular cell proliferation and macrophage infiltration are present.82  Recovery 
from this disease requires plasmin mediated fibrin degradation. Plasmin is 
activated by tPA and uPA that are produced in the kidney.45, 83, 84 In many 
glomerulonephropathies, fibrinolysis appears to be inhibited by increased local 
release of PAI-1.85  Urokinase receptor may also have a role in the long term 
development of glomerulosclerosis in these disease processes. Glomerular 
uPAR is increased in an accelerated model of nephrotoxic nephritis in the rat. 
Urokinase may facilitate local fibrinolysis by binding uPA and leading to 
degradation of the glomerular matrix.86 
2.12 Urokinase and Urokinase Receptor in the Ureter 
Little is known about uPA and uPAR in the ureter. In the ureter of healthy people 
uPA and uPAR exhibit weak to moderate immunohistochemical staining 
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in the cytoplasm of both urothelial and stromal cells.87 
2.13 Urokinase and Urokinase Receptor in the Urinary Bladder 
Urokinase and uPAR have been extensively evaluated in people with 
malignancy of the urinary bladder.88-90 Urokinase has increases significantly in 
malignant cell lines and is believed be a negative prognostic marker.89, 90 
Concentration of uPAR does not correlate with severity of disease.8 
The urinary bladder functions as an impermeable barrier. 46, 91 In 
mammals, sodium and potassium are transported across the epithelium of the 
urinary bladder from the urine to the interstitial space. Sodium transport occurs 
through amiloride-sensitive Na+ channels in the apical membrane. Once Na+ is in 
the cell, it is extruded across the basolateral membrane by Na+- K+ ATPase in 
exchange for K+ which is actively transported back into the cell via K+ channels in 
the basolateral cell membrane. On average there is one amiloride-sensitive Na+ 
channel in the rabbit urinary bladder for every 40 µm2 of apical membrane. These 
channels are hydrolyzed by endogenous uPA released from the kidney. After 
exposure to urokinase, the normal Na+ channel loses its amiloride and becomes 
unstable in the membrane.92 The significance of this relationship is unknown. 
In cows, the urinary bladder urothelium is the source of urinary 
plasminogen activators, including uPA. In other mammalian species, the kidney 
is the primary source of urinary plasminogen activators .46  The significance of 
this finding is unknown. 
2.14 Urokinase and Urokinase Receptor in the Prostate 
Evaluation of uPA and uPAR in the prostate is focused on prostate cancer 
in people and models of prostatic disease in mice and rats.93-95 The prostate 
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gland is comprised of different lobes that are easily distinguished in rats.96 In a 
study by Wilson, plasminogen activity varied significantly when the variables of 
age, region of the prostate and castration were evaluated. Activity in all lobes 
was low at 4 months and increased in the dorsal and anterior lobes at 31 months. 
Plasminogen activity in the lateral lobe did not change with age. Following 
castration, plasminogen activity increased by 3 to 5 fold in the ventral lobe in 4, 
18 and 31 month old rats. Involution also increased in the ventral lobe of the 4 
and 18 month old rats. These differences may reflect changes in cell function 
such as secretion, inflammatory tissue pathology, altered hormone regulation of 
these glands or unknown factors.97 
Ventral prostates in older Fischer 344 rats demonstrated 25 times greater 
plasminogen activator activity per unit of protein than juvenile rats. As rat aged 
the activity of urokinase versus tissue-type plasminogen activator changed. 
Urokinase is predominant in the 4 and 16 month old rats. Tissue-type 
plasminogen activator is more predominant in the 30 month old rats.100 These 
findings are based on amiloride activity which is selective as a urokinase 
inhibitor.100, 101 
In people, the prostate is more commonly divided into zones and the 
development of pathology is different for these specific zones.97  In men, 80% of 
prostate cancer is seen in the peripheral zone of the gland.17  Proteases are 
important in mediating cellular atrophy and changes in tissue organization which 
occur in normal development and in pathologic conditions. One group of these 
proteases is the plasminogen activators. Proteases may be important in 
remodeling the extracellular matrix in the prostate during development. In men, 
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several studies have shown that uPA is the predominant plasminogen activator in 
malignant and hyperplastic prostate tissue.17, 98, 99 
2.15 Urokinase and Urokinase Receptor in the Testicle 
Urokinase and urokinase receptor have been identified in spermatozoa of 
mice, rats, rhesus monkeys and men. 43, 50, 102-105 Mouse spermatozoa have uPA 
bound to the cell surface which is believed to be acquired from genital tract 
secretions and synthesized by epithelial cells in the caudal epididymis and vas 
deferens.43 Binding of uPA occurs due to synthesis and subsequent presence of 
uPAR by the germ cells during spermatogenesis.103 Urokinase is present in 
Sertoli cells of the rat  and rhesus monkey and the Sertoli cells have been shown 
to secrete uPA in cycles with tPA.50, 106 Urokinase production is decreased in 
cultured Sertoli cells of the rat by the presence of follicle stimulating hormone.104 
Urokinase is higher in the first fraction of ejaculate than in the second, suggesting 
a mainly prostatic origin. In cases of azoospermia in men, concentrations of 
measured uPA are much lower than in normal semen.105  The role of uPA and 
uPAR in semen is still unknown but may be linked to cases of infertility.  
2.16 Urokinase and Urokinase Receptor in the Urethra 
 Urokinase and urokinase receptor in the urethra have not been reported. 
2.17 Urokinase and Urine 
 The ability of urine to lyse clots has been recognized for many years.107-109 
Fibrinolytic ability is known to come from urokinase, which is excreted into the 
urine from the kidney in most species. Urine samples from people have been 
collected in large quantities and dialyzed using column chromatography to 
evaluate the forms of urokinase in urine and to measure their activity.110 Both 
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high and low molecular weight forms of urokinase are present in urine from 
people.110, 111  
2.18 Clinical Importance of the Fibrinolytic System 
2.18.1 Coagulopathies and Hypercoagulation 
Coagulation and fibrinolysis are believed to occur simultaneously during 
the active state of hemostasis. Two pathologic conditions of this system are 
coagulopathies and hypercoagulable states.28  
A coagulopathy due to derangements in the fibrinolytic system leads to 
excessive fibrinolysis within the tissues. Increased circulating tissue plasminogen 
activator within the vasculature would increase intravascular fibrinolysis.  
Decreased concentration of α2-antiplasmin in circulation can produce a 
coagulopathy.112-114 α2-antiplasmin concentration will decrease in response to the 
activation of plasminogen which occurs in many fibrinolytic states.112  A PAI-1 
deficiency could be the cause of increased tPA and may also increase circulating 
uPA since PAI-1 inhibits both tPA and uPA.113 Antihemostatic effects of fibrin 
degradation products in conditions such as in disseminated intravascular 
coagulation (DIC) also lead to coagulopathies.  
Hypercoagulation is the result of activated coagulation factors with 
decreased resistance to thrombosis. In cases of inflammation and infections in 
the horse and cow, consumption of protein C and antithrombin decreases the 
host anticoagulant response to coagulation. In other words, a lack of 
plasminogen activators secondary to increased PAIs and consumption of 
circulating anticoagulants is occurring within the body.9 Therefore, thrombosis 
occurs when inappropriate increases in fibrinolytic inhibitors reduce fibrinolysis. 
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Inflammation, and ischemia can cause thrombosis by decreasing plasminogen, 
plasminogen activators and Protein C. Antithrombin III, which inactivates Factor 
Xa and thrombin, is also decreased in these disease states.3 Hypercoagulation 
precedes clinical DIC.   
Secondary fibrinolysis is a physiologic response to systemic large vessel 
and microvascular thrombosis that occurs during hypercoagulation and DIC. 
Excessive fibrin forms independent of activation of the coagulation cascade.  
Inflammatory cells and platelets carry their own internal stores of 
plasminogen activators and inhibitors to sites of inflammation and infection. 
Urokinase receptor is produced and present on the cell membranes of 
granulocytes and monocytes.  Urokinase will bind to uPAR on granulocytes and 
monocytes and be introduced to inflammatory sites by migrating cells. The 
urokinase-type plasminogen system consisting of uPA, uPAR and inhibitors plays 
an important role in neutrophil, macrophage and platelet activation, adhesion, 
migration and extravasation.115 Granulocytes have the highest expression of 
uPAR among blood cells. Tissue plasminogen activator and PAI-1 and 2 are also 
present in granulocytes and monocytes. PAI-1 and uPA are present in the 
platelets of dogs.71 Upregulation of the inflammatory systems in a case such as 
sepsis causes derangements in the coagulation/hemostatic system, including 
consumption of coagulation factors, increased coagulation/hemostatic activity, 
and reduced fibrinolysis. 116, 117  During sepsis circulating leukocytes release uPA, 
tPA, PAI-1 and PAI-2. Which, in conjunction with fibrin deposits and with 
inflammatory responses, may cause the persistence of fibrin, thrombosis and 
subsequent multiple organ failure.21   
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Table 2.3 Pathophysiologic factors that regulate fibrinolysis/thrombolysis.9 
Promote Limit 
Plasminogen incorporation into a thrombus via 
fibrin binding 
Fibrin crosslinking by factor XIIIa 
Platelet clot retraction Low ratio of tPA to plasminogen activator 
inhibitor (PAI-1 or 2) 
Endothelial cell and macrophage biosynthesis 
of tPA and uPA 
Low ratio of endothelial surface to thrombus 
volume in large vessels 
Binding of tPA to fibrin Efficient inhibition of free plasmin by α2-
antiplasmin 
Enhanced tPA or uPA activity in the presence 
of fibrin 
α2-antiplasmin impairs plasmin binding to fibrin 
Protection of plasmin (bound to fibrin) from α2-
antiplasmin binding 
Binding of α2-antiplasmin to fibrin 
Plasmin activation of factor XII Increased activated protein C decreases PAI-1 
activity 
2.18.2 Urokinase and Urokinase Receptor in the Vascular 
System  
 
Fibrinolysis is initiated in a damaged vessel wall following production of 
tissue-type and urokinase-type plasminogen activators by the endothelial cell.118 
Increased plasminogen activator expression in the vessel wall facilitates vascular 
smooth muscle migration and cell proliferation for vessel healing by initiating a 
proteolytic cascade of matrix degradation.118 Angiogenic properties of uPAR are 
related to binding of and improving adhesion properties of vitronectin, which is an 
important extracellular matrix protein in angiogenesis during vascular remodeling 
and repair.31 In normal saphenous veins and internal mammary arteries of 
people, tPA, uPA and PAI are minimally expressed in the endothelium, intimal 
and medial smooth muscle cells. The uPAR is observed on the endothelium of 
normal saphenous vein or internal mammary artery but absent on the smooth 
muscle cells.118  A recent study of mouse arteriogenesis suggested that uPA 
itself is the most important promoter of leukocytes required for collateral artery 
growth. Association of leukocyte infiltration with arteriogenesis is strongly 
reduced in uPA-/- but not in uPAR-/- or tPA-/- mice.119 
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2.18.3 Urokinase and Urokinase Receptor in Wound Healing 
 
Urokinase and uPAR are important in clot lysis, and the inflammatory, 
proliferative and maturation phases of wound healing. During clot lysis, urokinase 
is released from the tissues and inflammatory cells.  Urokinase cleaves 
plasminogen to plasmin which leads to fibrin breakdown.3 In the inflammatory 
phase, uPA and uPAR aid in attraction, adhesion and migration of neutrophils 
and monocytes into the injured tissue.9 During the proliferative phase, uPA is 
important in stimulating the growth of capillaries into the granulation bed through 
its angiogenic properties. In the maturation phase, uPA-uPAR complexes 
continue to contribute to break down of fibrin in the provisional matrix to allow 
fibroblasts to enter and make true extracellular matrix. Urokinase and urokinase 
receptor would also aid in epithelialization because of the high affinity for uPAR 
to vitronectin, which is important in allowing epidermal cells to interact with the 
underlying extracellular matrix.31, 120  
In a rat model of tendon healing, uPAR and uPA accumulation in the 
healing tendon was regulated hin a time dependant manner. Changes in 
concentrations of uPA and uPAR correlated with phases of wound healing. Both 
uPAR and uPA expression peaked at day 14 and decreased at day 21 post-
injury. 60  
2.19 Summary 
The fibrinolytic system has many roles both within and outside of the 
vascular system. Urokinase is an activator of the fibrinolytic system. Urokinase is 
present in parts of the urinary tract of mammals and is excreted in urine. The 
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exact purpose of urokinase in urine is unknown but it may prevent obstruction of 
the urinary tract by blood clots and fibrin. 
Identification and quantification of uPA in the urine of dogs would suggest 
that uPA has some role in the health of the canine urinary tract. Localization of 
uPA in the prostate of canines may be important since castration prior to urinary 
diversion surgery may be beneficial in decreasing post-operative bleeding. Use 
of drugs such as ε-aminocaproic acid that competitively inhibit plasminogen 
activator substances have been used successfully in people to inhibit uPA and 
decrease bleeding; however dosages have not been established in dogs. If uPA 
is identified in urine from dogs in significant concentrations, the possibility of 
exploring its role in unhealthy dogs and the use of pharmacologic agents in 
manipulating its activity can be explored. 
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Chapter 3 Hypothesis and Objectives 
3.1 Overall goals 
 
This study demonstrated the presence of urokinase (uPA) in canine urine 
and quantified it in normal male and female dogs using an ELISA and a 
fluorogenic activity assay. This study also demonstrated the presence of 
urokinase and urokinase receptor in the tissues of the canine urinary tract, both 
male and female, using immunoprecipitation, SDS PAGE / Western Blot Analysis 
and immunohistochemistry techniques. 
3.2 Hypothesis and Specific Objectives  
3.2.1 Hypothesis 
1. Urokinase will be present in urine from healthy dogs.  
2. Urokinase concentration will be higher in urine from intact male 
dogs than intact or neutered female dogs.  
3. Urokinase concentration will be higher in urine from intact male 
dogs than neutered male dogs. 
4. Urokinase concentration will be the same in intact and neutered 
female dogs. 
5. Urokinase concentration will be similar in urine from intact female 
dogs and neutered male dogs. 
6. Urokinase and urokinase receptor will be present in the canine 
urinary tract. 
7. Antibodies directed against human and mouse urokinase will 
recognize urokinase and urokinase receptor in the urinary tract and 
from healthy dogs. 
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3.2.2 Specific Objectives 
• Demonstrate and quantify urokinase in urine from healthy dogs. 
• Demonstrate presence of urokinase-like antigen and urokinase 

















Chapter 4 Sample Selection and Preparation 
 
4.1 Sample Populations 
4.1.1 Sample Population for Urine Collection 
Fifty four client owned dogs presented to the LSU SVM Small Animal 
Hospital Companion Animal Surgery Service that met the following inclusion 
criteria were used. The dogs were treated according to the regulations of the 
Institutional Clinical Protocol Committee. The dogs were divided into four groups: 
16 intact males, 15 sterilized males, 9 intact females, 12 sterilized females.  
Inclusion criteria: 
1. No physical or biochemical evidence of current renal or lower 
urinary tract disease (appendix table 1).  
2. No antibiotic administration in the previous 2 weeks.  
3. Blood and urine samples being taken for reasons other than this 
study (appendix table 1). 
4. Normal physical exam, complete blood count, serum 
biochemistry and urinalysis (appendix table 1). 
4.1.2 Sample Population for Urinary Tract Tissue Collection 
Eleven dogs were used for tissue collection; 5 intact males, 2 neutered 
males, 4 intact females 
The following inclusion criteria were used for case selection:  
1. Euthanasia for reasons other than urinary tract or renal disease.  
2. No gross pathologic signs of urinary tract or renal disease. 
Samples were collected at the time of euthanasia.  
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4.2 Sampling Technique 
4.2.1 Urine Collection 
A minimum of 3 ml of voided urine was collected into a clean receptacle 
and transferred to 50ml polypropylene tubes (352070, Becton Dickenson, 
Franklin Lakes, NJ) for immediate freezing and storage at -75°C. Freezing and 
thawing up to five times does not appear to affect urokinase activity.1 The entire 
volume of urine collected and the date were recorded for each sample. 
A second urine sample was collected from each dog using a cystocentesis 
technique. This urine was then transferred using a sterile needle to a sterile 
vacutainer tube. Each sample was then plated on blood agar and Maconkey 
plates, incubated for 72 hours at 37ºC and evaluated every 24 hours by the 
principal investigator for presence of bacterial colony growth.  
4.2.2 Urinary Tract Tissue Collection 
1. Kidney: A 2 cm X 1cm full thickness wedge of cortex and medulla was 
taken from the middle portion of the kidney.  
2. Ureter: A 2 cm full-thickness section was taken from the ureter contra 
lateral to that of the kidney biopsy. 
3. Urinary bladder: A 2 cm full-thickness 2 cm sample section was taken 
from the ventral wall. 
4. Prostate: A 1 cm X 1 cm wedge was taken from one lobe of the 
prostate. 
5. Urethra (male dogs): A 2 cm full-thickness section was taken from the 
prostatic and penile regions of the urethra. 
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6. Urethra (female dogs): A 2cm full-thickness section was taken from the 
middle of the urethra. 
7. Testicle: A 2 cm full-thickness wedge biopsy was taken from one 
testicle. 
4.3 Sample Preparation 
4.3.1 Urine Preparation 
All urine was thawed in the polypropylene storage tubes at room 
temperature and concentrated using Amicon Ulltra-15 PLTK Centrifugal Filter 
Units with 30kDa membranes  (UFC903024, Millipore Corporation, Burlington, 
MA) and Amicon Ultra-4 PLHK Centrifugal Filter Units with 100kDa membranes 
(UFC810024, Millipore Corporation, Burlington, MA). 
Steps in urine preparation and concentration: 
1. The urine was centrifuged in the original polystyrene tubes at 
2500rpm for 10 minutes to pull down any debris. 
2. Cleared urine was transferred to clean polystyrene tubes leaving 
the pelleted debris at the bottom of the original tube. 
3. The urine was transferred to 100kDa filter units and volume was 
recorded. 
4. The urine in the 30 kDa filter units was centrifuged at 2500rpm for 
45 minutes. This allowed separation of the urine into two fractions. 
The fraction containing proteins greater than 30 kDa was retained 
in the upper chamber. The fraction containing proteins less than 30 
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kDa passed through the filter and was deposited in the lower 
chamber. 
5. Urine in the upper chamber (with proteins greater than 30 kDa) was 
removed, the volume was measured and the urine was placed in 
the 100 kDa filter tubes. The urine in the 100kDa filter units was 
centrifuged at 2500rpm for 30 minutes. This allowed separation of 
the urine into two fractions. The fraction containing proteins greater 
than 100 kDa was retained in the upper chamber. The fraction 
containing the remaining proteins between 100 kDa and 30 kDa 
passed through the filter and was deposited in the lower chamber.  
This fraction should contain urokinase which has a molecular 
weight of 33kDa in the short chain form and 53kDa in the heavy 
chain form. 
6. Urine in the lower chamber (with proteins between 30 kDa and 100 
kDa) was removed, the volume was measured and the urine was 
placed in placed in 1.5ml microcentrifuge tubes (20170.022, VWR 
International, Suwanee, GA). 
7. Urine samples were frozen at -20°C until evaluation. 
4.3.2 Tissue Preparation for Morphological Study 
Tissue samples collected from nine dogs (four intact males, two castrated 
males and three intact females) were immediately frozen in Tissue-Tek OTC 
compound (4583, Sakura Finetechnical Co., Ltd., Tokoya, Japan) and stored at -
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70 ºC for later paraffin embedding or desiccation and processing with RIPA 
buffer.  
 Samples collected from two dogs (one intact male and one intact female) 
were placed in formalin immediately for later comparison with the fresh frozen 
samples to identify any freezing artifacts. 
Paraffin sections (4um) were cut and stained with hematoxylin and eosin 
or used for immunohistochemical staining. 
4.4 References 
1. Wilson MJ, Ditmanson JD, Sinha AA, Estensen RD. Plasminogen 
activator activites in the ventral and dorsolateral prostatic lobes of aging 
















Chapter 5 Fluorogenic and ELISA Assays for Urokinase in Urine 
 
5.1 ELISA Assay Introduction 
Quantification of proteins in tissues or fluids can be achieved in several 
ways. An ELISA can measure both the inactive and active forms of an antigen by 
measuring antibody-antigen interaction which is linked to an enzyme which 
reacts on a chromogenic substrate. This substrate causes production of a color 
change. The color intensity is measured by a plate reader based on the number 
of antibody-antigen complexes formed. Success with this method requires 
measurable amounts of the antigen of interest.1 
The direct ELISA, Indirect ELISA and Sandwich ELISA are the basis of all 
ELISAs. 2  
The direct ELISA is the simplest. Only one primary antibody is used and 
this antibody is directly conjugated with an enzyme. Addition of a substrate 
allows visualization of the reaction.2  
The indirect ELISA is similar to the direct ELISA except that the antigen is 
targeted initially by an unlabelled detecting or primary antibody. An antispecies 
antibody, which is bound to a conjugated enzyme, is then added. Addition of a 
substrate specific for the enzyme allows detection of the reaction.2 
The sandwich ELISA can be subdivided into direct and indirect sandwich 
ELISAs. In both the primary antibody is passively attached to a solid phase plate 
by incubation in a buffer. After washing away the free antibodies, the antigen of 
interest is added and captured by the coating antibodies. For the direct sandwich 
ELISA a single antigen-specific antibody with an enzyme label is added; for the 
indirect sandwich ELISA, an unlabelled antibody is used followed by a second 
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enzyme labeled-antibody. For both sandwich ELISAs, a substrate specific for the 
enzyme is added to visualize the reaction.2  
Reading of the reactions or measurement of the color produced in the 
ELISA is generally performed with the use of a plate reader. The plate reader 
contains a spectrophotometer which quantifies the degree of color change 
obtained with particular enzyme/chromophore systems. The wavelength must be 
set for the absorption maxima of the chromophore. Plates can be read only 
qualitatively by the naked eye. A plate reader is required to more able to detect 
subtle differences in absorption between wells in the plates and give a 
quantitative analysis.2 
5.2 ELISA for Urokinase Quantification in Urine 
 Urokinase is present in tissues and urine of mammals in active and 
inactive enzymatic forms.3-6  An ELISA can measure both the active and inactive 
urokinase in a sample. ELISA kits for urokinase are available. The antibodies in 
these kits are directed towards human and mouse urokinase. We created a direct 
sandwich ELISA using antibodies which we had already shown to successfully 
bind with canine urokinase in western blot analysis, immunoprecipitation and 
immunohistochemistry. (Chapter 6, section 6.6 and chapter 7, section 7.4)  
5.2.1 Samples 
 Fifty-four urine samples were collected from healthy dogs (appendix table 
1) and prepared as described in chapter 4, Sample Selection and Preparation.  
Each sample was allowed to thaw at room temperature prior to addition to the 
sample wells. Thirty-eight samples were run in duplicate (appendix table 3). 
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5.2.2 Antibodies, Purified Enzymes and Buffers 
• Primary Coating Antibody - Mouse Monoclonal to mouse uPA – A capture 
monoclonal antibody produced in a uPA knockout mouse. IgG fraction 
purified by Protein A Sepharose. (H77A10, Molecular Innovations, 
Southfield, MI) 
• Secondary Labeled Antibody - Rabbit anti-human uPA IgG fraction, biotin 
labeled – Biotin labeled polyclonal antibody (host rabbit). IgG fraction 
purified by protein A sepharose. (ASHUPA-GF-BIO, Molecular 
Innovations, Southfield, MI) 
• Standard Control Enzyme - Human HMW Urokinase – Prepared from 
human urine as the two-chain form. (UPA-HTC, Molecular Innovations, 
Southfield, MI) 
• General Buffer - Phosphate Buffered Saline (PBS) – Fisher Gram-Pac 
Buffer pH 7.41. (B-82, Fisher Scientific, Fair Lawn, NJ) 
• Blocking Buffer - 2% bovine serum albumin (BSA) (0332-25G, Amerseco, 
Solon, OH) in PBS  
• Dilution Buffer - 0.5% BSA (0332-25G, Amerseco, Solon, OH) in PBS  
• Washing Buffer – 0.5% Triton-X-100 (161-0407, Bio-Rad Laboratories, 
Hercules, CA) in PBS  
• Substrate – Peroxidase Solution B, H2O2, (50-65-00, KPL, Gaithersburg, 
MD) 
• Chromophore – TMB (50-76-01, KPL, Gaithersburg, MD) to interact with 
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Horseradish peroxidase enzyme to produce a blue color change in the 
ELISA wells 
• Stop Agent - 0.1% H2SO4, when added to the well this stops the reaction 
between TMB and H2O2, decreases the pH and changes the reaction to a 
yellow color. 
5.2.3 ELISA Technique 
 Standardization: Ninety-six well plates were incubated to determine the 
optimal antibody dilution for the ELISA with 100µl of mouse anti-mouse uPA 
antibody at 1:250, 1:500, 1:1000, 1:2000, 1:4000 and 1:8000 dilutions at room 
temperature overnight. All samples and standards were run in duplicate. After 
incubation, 300µl of the blocking buffer was added to the wells for 1 hour at room 
temperature. The wells were then washed three times with washing solution and 
blotted. Log dilutions of 100µl of pure uPA diluted in PBS were then added to 
each of the wells. The standard curve ran from 1 µg to 1 pg in serial log dilutions. 
One row was left as blank. The uPA was incubated at room temperature for 2 
hours. The wells were again washed three times with washing solution. The 
rabbit anti-human uPA antibody was then added at 1:1000 dilutions in a volume 
of 100µl at room temperature for 2 hours. The wells were again washed 3 times 
with the washing buffer. Streptavidin conjugated to horseradish peroxidase 
enzyme was then added at a volume of 100 µl for 30 minutes. The chromophore 
was then added for 15 minutes. After this time the reaction was stopped with 
0.1% sulfuric acid and the reaction was read in a plate reader at 405 nm.  
 Urine samples were run in the same manner as described. The dilution of 
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the mouse anti-mouse uPA antibody was 1:8000. The uPA standard was diluted 




Figure 5.1 Direct sandwich ELISA for canine uPA. The addition of the substrate H2O2 results in 
the following reaction H202 → H20 + Ö. The resultant free oxygen radical reacts with the 
chromogen TMB to produce a blue color change. Stopping the reaction with H2SO4 decreases the 
pH causing the end color to be yellow.  
 
5.2.4 Problems 
The large number of dilutions was required to choose the primary antibody 
dilution for the test samples was due to presence of background in the wells. 
Ideally one would like to see background readings close to 0 to ensure that 
samples with low concentrations of the antigen of interest are not blocked out. In 
our case, the background was likely due to the non-specific binding of the rabbit-
polyclonal antibody to the mouse-monoclonal antibody. Even with a dilution of  
1:8000, some background was still evident; however the level was acceptable 
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acceptable without loss of uPA delectability.  
5.3 Activity Assays Introduction 
Chromogenic and fluorogenic substrates are used to measure only the 
active form of the enzyme in question.3-7 Enzymes are proteins which catalyze 
most of the chemical reactions in the body. In the case of uPA the activity is 
thrombolytic activity.8 The chemical compound upon which the enzyme exerts its 
catalytic activity is the substrate.7 Proteolytic enzymes degrade their substrates, 
proteins and peptides by hydrolyzing one or more peptide bonds. 
5.3.1 Chromogenic Assays 
Chromogenic substrates are peptides which react with proteolytic 
enzymes causing color changes based on the level of activity.3-6 Chromogenic 
substrates are made up of a protecting group, amino acid residue(s), side chain 
modification if applicable and the chromophore. The most commonly used 
chromogenic substrate for measurement of uPA activity in tissues, plasma and 
urine is S-2444 (Chromogenix, MöIndal, Sweden) from Diapharma. The chemical 
formula for this compound is <Glu-Gly-Arg-pNa HCl (L-Pyroglutamyl-glycyl-L-
arginine-p-nitroaniline hydrochloride).62 The reaction is simple: 
<Glu-Gly-Arg-pNa      Enzyme→       <Glu-Gly-Arg-OH + pNa 
The method for determining activity is based on the difference in 
absorbance (optical density) between the pNa formed and the original substrate. 
The rate of pNa formation, i.e. the increase in absorbance per second at 405nm, 
is proportional to the enzymatic activity and is determined with a 
spectrophotometer.62 
This substrate has been used to measure uPA activity successfully in 
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human urine, however, the method of purification used was gel filtration and the 
quantities of urine used were large.3-6 In our study we did not purify the urine but 
rather concentrated it using biologic filters to contain molecular weight proteins 
between 30 kDa and 100 kDa. This allowed us to decrease the quantity of urine 
collected since collection of large volumes of urine from one dog was often 
impossible. Filtering the urine did not alter the yellow color of urine. Since the 
wavelength used for measuring the reaction with S-2444 and other chromogenic 
substrates is 405nm, which is the yellow wavelength; the filtered urine could not 
be accurately assessed with this method as the yellow color interfered with the 
results. 
5.3.2 Fluorogenic Assays 
Fluorogenic substrates measure activity along the same principal as the 
colorimetric substrates. These substrates contain a fluorophore rather than a 
chromophore and cleavage of this fragment is determined by the fluorescent 
activity.7 The substrate used to evaluate uPA excites at 360-380nm with 
emission at 440-460nm.9 These reactions can also be performed in 96 well plates 
however the wells must be have black sides and black or clear bottoms to 
prevent interference from neighboring wells. This method can quantify the 
concentration of uPA in the urine. The fluorescence activity is compared to a 
standard fluorescence curve derived from with known concentrations of pure 
human urokinase.  
5.4 Fluorogenic Activity Assay for Urokinase Quantification in Urine 
The fluorogenic substrate used in our experiment was Urokinase 
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Substrate III from Calbiochem. The chemical composition of this substrate is 
similar to that of S-2444 with the exception of the end group Glutaryl-Gly-Arg-
AMC, AMC being the fluorophore. The yellow color of the urine does not interfere 
with the fluorescence however urine does contain xanthenes which have 
autofluorogenic properties. Fortunately the xanthenes tend to excite at higher 
wavelengths than that of uPA activity. To verify lack of interference with our 
samples, random samples were run without the substrate at the required 
excitation and emission for the Glutaryl-Gly-Arg-AMC reaction. No fluorescent 
activity was noted.  
5.4.1 Samples 
 Urine samples were collected and processed as described in chapter 4, 
Sample Selection and Preparation. Each sample was allowed to thaw on ice to 
4ºC prior to addition to the sample wells. Fifty samples evaluated in the assay. 
5.4.2 Substrates and Buffers 
• Fluorescence Buffer – 6g Tris, 7.9g TrisHCL adjusted to pH 7.5-7.7; 1g 
polyethylene glycol(6000); 5.8g Sodium Chloride; 3.78g D-Mannitol, in one 
liter of distilled water. 
• Substrate – Urokinase Substrate III, Fluorogenic, Z-Gly-Gly-Arg-AMC, HCl 
(672159, Calbiochem, San Diego, CA) 
• Enzyme - Human HMW Urokinase – Prepared from human urine as the 
two-chain form. (UPA-HTC, Molecular Innovations, Southfield, MI) 
5.4.3 Fluorogenic Assay Technique 
The technique used was modified from a technique described by Enzyme 
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Figure 5.2 Schematic representation of fluorescence assay for uPA using Urokinase Substrate III. 
When the Urokinase Substrate III is added to the uPA in the fluorescence buffer, the active uPA 
cleaves the AMC group from the Urokinase Substrate III. The AMC is excited at a wavelength of 
360/380 nm and the fluorescence is emitted at a wavelength of 440/460 nm. The diagrams 
represent one well in the 96 well plate. Activity is read at time 0 and 5 minutes. 
 
Systems Products.10  We modified volume of urine to allow samples to be run in 
96 well Microplat Standard SUR plates (BD 353293, Becton Dickenson, Batavia, 
IL) 
 All samples were run in triplicate and all reactions were performed at 
approximately 4ºC. Urokinase standard curves were run with each plate using 
pure human uPA in serial dilution starting at 2 µg and ending at a 1:64 µg 
dilution. With the plates on ice, 182µl of the fluorogenic buffer was added to each 
test well. Eight microliters of pure uPA or sample was then added to each well. 
This mixture was allowed to equilibrate for 15 minutes on ice. Following the 
equilibration, 8 µl of the Urokinase Substrate III was added to each well. The 
plate was then placed in a Fluorescence Plate Reader and agitated for 6 
seconds. The plates were read at time 0 and 5 minutes at excitation maxima of 
360/40 and emission maxima of 460/40nm (figure 5.2). Standard curves were 
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generated for each plate and concentration based on activity was translated from 
the standard curve (appendix figure 1). 
5.5 Statistical Analysis 
 The urokinase concentration and the urokinase enzymatic activity (EA) 
was corrected for the volume of concentrate:original volume of urine by 
multiplying the concentration of the tested sample by the original 
volume/concentrated volume. The urokinase concentration and the enzymatic 
activity were expressed as units/mg Cr /uL urine. 
The urokinase concentration and the enzymatic activity was also adjusted 
for the concentration of creatinine in the urine. The creatinine-adjusted urokinase 
concentration and the enzymatic activity were then expressed as units/mg Cr /mL 
urine.  
The urokinase concentrations and the creatinine-adjusted urokinase 
concentrations were plotted and the distribution of the data visualized and 
described. Normality was tested using the Shapiro-Wilk statistic with the null 
hypothesis of normality rejected at p<0.05.  Since all data was not normally 
distributed, comparisons were made between gender (male vs female) and 
between sexual status (male neuter, male intact, female spayed, female intact) 
using the Wilcoxon-rank sum test and the Kruskall-Wallis test, respectively.  
Significance was determined at p<0.05.  
The linear correlation between the urine creatinine concentration and the 
urokinase concentration was explored using Spearman’s rank test. The 
Spearman correlation coefficient rho (ρ) is reported. Moderate correlation was 
considered if ρ > 0.65; marginal correlation if ρ > 0.40.  
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SAS (PROC CORR, PROC NPAR1WAY, PROC UNIVARIATE) was used 
for the analysis. (SAS v 9.1, SAS Institute, Cary, NC). 
5.6 Results 
Urokinase concentration - The distribution for the urokinase concentration 
and the creatinine-adjusted urokinase concentration for each group was skewed 
to the right and the null hypothesis of normality was not rejected, except for the 
urokinase concentration of females and castrated males (figs 5.3 and 5.4, tables 
5.1 and 5.2 and appendix table 3). There was no significant difference between 
males and females or among sexual status for urokinase or creatinine-adjusted 
urokinase concentrations.   
There was poor to marginal correlation between the creatinine 
concentration and the urokinase concentration in the urine from male dogs 
(ρ=0.24), male castrated dogs (ρ=0.49) and female dogs (ρ=0.49). There was 
moderate correction for female spayed dogs (ρ=0.67) (fig 5.5). When all female 
dogs were grouped together, the correlation was marginal (ρ=0.36). 
EA concentration – The distribution for the EA and for the creatinine-
adjusted EA for each group was heavily skewed to the right and the null 
hypothesis of normality was not rejected (figs 5.6 and 5.7 and appendix table 2) 
5.7 Discussion 
 Urokinase is present in urine of healthy dogs in small but measurable 
quantities. The ELISA assay measured urokinase in both the active and inactive 
state. The fluorescent assay measures only active uPA in the urine.  
Sampling technique created additional work in this experiment because 
we used variable volumes in our samples and concentrated them to variable 
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Figure 5.3 ELISA assay of canine urine versus dog groups, ng urokinase/µl urine 
 
Figure 5.4 ELISA assay of canine urine versus dog groups, ng urokinase/mg creatinine/µl urine 
 
Table 5.1 Standard Deviation, coefficient of variation, median and quartiles for volume corrected 
ELISA results  
 
 Female Female Spayed Male Male Castrated 
Mean 381.49 1007.10 890.44 366.41 
Std Deviation 269.82 924.19 928.41 272.55 
Coeff of Variation 70.73 91.77 104.26 74.38 
Minimum - 53.89 114.87 81.43 -21.18 
Lower Quartile 199.71 329.63 185.42 106.91 
Median 305.15 612.38 395.19 379.21 
Upper Quartile 617.58 1652.52 2030.64 598.48 
Maximum 825.39 2944.16 2524.30 799.36 
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Table 5.2 Standard Deviation, coefficient of variation, median and quartiles for volume and 
creatinine corrected ELISA results.  
 
 Female Female Spayed Male Male Castrated 
Mean 14.12 63.85 59.59 32.39 
Std Deviation 9.93 66.35 92.98 27.47 
Coeff of Variation 70.38 103.92 156.03 84.81 
Minimum -2.42 7.56 3.69 -1.65 
Lower Quartile 6.44 17.48 9.64 10.63 
Median  15.06 45.15 24.89 23.09 
Upper Quartile 19.89 68.26 69.31 55.30 
Maximum 34.67 226.29 386.90 86.30 
 
 
Figure 5.5 Fluorescent Activity assays of canine urine versus dog groups, emission activity (EA) 
of urokinase / mg creatinine/ µl urine 
 
 





Figure 5.7 Fluorescent Activity assays of canine urine versus dog groups, emission activity (EA) 
urokinase / µl urine  
 
Table 5.3 Standard Deviation, coefficient of variation, median and quartiles for volume corrected 
fluorescent assay results  
 
 Female Female Spayed Male Male Castrated 
Mean 0.001 0.001 0.001 0.001 
Std Deviation 0.001 0.002 0.002 0.002 
Coeff of Variation 158.31 176.02 173.48 167.67 
Minimum 0 0 0 0 
Lower Quartile 0 0 0 0 
Median 0 0 0 0 
Upper Quartile 0.001 0.001 0.002 0.001 
Maximum 0.003 0.005 0.007 0.006 
 
Table 5.4 Standard Deviation, coefficient of variation, median and quartiles for volume and 
creatinine corrected fluorescent assay results.  
 
 Female Female Spayed Male Male Castrated 
Mean 0.03 0.07 0.10 0.07 
Std Deviation 0.06 0.12 0.18 0.10 
Coeff of Variation 188.24 166.06 187.09 146.21 
Minimum 0 0 0 0 
Lower Quartile 0 0 0 0 
Median  0.003 0 0 0 
Upper Quartile 0.04 0.13 0.09 0.001 
Maximum 0.19 0.34 0.65 0.32 
 
volumes. Doing this required that we calculate concentration factors for each 
urine sample and apply this number to the values obtained in each assay prior to 
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evaluation. This method was necessary in our study because we did not have 
any prior knowledge of the expected concentration of urokinase in canine urine. 
We collected maximum volumes in an attempt to ensure we did not miss 
urokinase because the volume was too small. If the expected concentration of a 
protein is known per unit of volume, one can start with and end with equal 
volumes of the urine or other sample to eliminate this step. With the results from 
the data we collected, in future studies we could use uniform start volumes of at 
least 3 mls and end volumes of at least 150 µl.  
 Urokinase activity has been measured directly by means of chromogenic 
substrates such as S-2444 which measure the amidolytic determination of 
urokinase activity in purified preparations and urine.4 This method requires a 
colorless sample as the yellow color of xanthenes in the urine interferes with the 
spectrum for measuring color change in the chromogen of S-2444 and other 
similar compounds. To purify the urine for this technique, gel chromatography is 
used to recover only the purified urokinase from samples. This requires large 
volumes of urine which are difficult to collect from dogs. This problem led us to 
instead choose the fluorescent assay as a means of measuring the active uPA in 
the urine samples collected from the dogs.  
 The technique used was adapted from a technique described by Enzyme 
Systems Products.10 The original technique was run in larger wells with larger 
volumes of buffer, enzyme and sample and was intended for use in plasma. To 
ensure that the autofluorescent properties of urine did not interfere with the 
sample reading urine samples were placed in wells without enzyme. They 
showed no fluorescence. The chemical, Z-Gly-Gly-Arg-AMC, HCl, has affinity for 
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urokinase as was demonstrated by its activity on pure urokinase in the standard. 
This chemical has also been used for evaluation of urokinase activity in plasma 
but not in urine.  
 Results In the fluorescence assay showed high variability, as 
demonstrated by the slopes of the standard curves. The variable readings in our 
assay could be the result of many issues. Using urine which had not been 
dialyzed by gel filtration left a sample which was still high in organic salts. This 
may have interfered with the reaction between the urine and the fluorescent 
substrate. The sample volumes placed in each well were very small, 8µl. This 
leads to increased risk of error by the person filling the wells. Use of a 
multichanel pipette would have decreased that risk but multichanel pipettes are 
not made to handle volumes smaller than 10 µl. Errors made with small volumes 
include leaving the sample on the side of the well, and not completely emptying 
the pipette when adding the sample. Either incident would dramatically change 
the result when the activity is volume dependant. A third area for error was also 
due to the fact that a multichanel pipette was not used. This assay is time 
sensitive, with measurements taken at time 0 and 5 minutes.  Although we tried 
to minimize the error associated with this problem by plating multiple plates with 
fewer samples, this probably also factored into the final values. All of these 
sources of error affected the results of our standard curves resulting in a lot of 
variability from plate to plate. This made comparison of values from plate to plate 
using the generated standard curves impossible. To enable comparison of all the 
plates we transformed the standard curves using a global fit standard curve, 
which averaged the readings of all the standard curves creating to make one of 
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best fit, thereby creating an artificial curve. The fluorogenic readings from each 
plate were then plotted along this new standard curve to extrapolate 
concentrations for each sample. In an ideal situation one would be able to use 
the same standard curve for every plate because the protocol would have very 
little variance from run to run. Methods for improving the variability in our assay 
would improve our results. Larger volumes of urine and substrate would help to 
decrease the effects of dilution or concentration if the volume varied slightly 
between wells. In most assays the minimum repeated volume is 50 µl, which 
decreases the risk of pipette induced error. Using larger volumes of the substrate 
also increases the cost of the assay considerably. Use of a multi-channel pipette 
to load the samples and substrate would decrease the time involved and the 
variability between wells. Switching to 24 well plates would allow larger volumes. 
All of these things together would decrease the variation considerably and maybe 
allow a repeatable standard curve and comparison of values without transforming 
the data. 
 Due to the extreme variability in results I do not feel that the 
concentrations obtained in the fluorescence activity assay could be taken as 
accurate concentrations (appendix table 2). I do feel that for those samples in 
which a value was obtained, that value is a measure of the urokinase activity in 
the volume of urine placed in the well. The comparison between groups is also of 
limited value. There may be differences between the groups that are not evident 
because the higher values in the actual plate would have been lowered to fit the 
global standard and the lowest values would have been raised. This results in 
less difference between the highest and lowest values. If there were a large 
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difference in activity between the groups we may still have seen a difference 
despite the large variation in our samples due to pipette error. 
 The ELISA assay appeared to produce less variable results (appendix 
table 3), however, the amount of background in the ELISA was higher than 
desired. The high background was likely due to the non-specific binding of the 
rabbit-polyclonal antibody to the mouse-monoclonal antibody. This could be 
further decreased by either increasing the dilution of secondary labeled antibody 
to 1:2000 or further, or by passing the rabbit antibody through a mouse 
immunoglobulin column to remove the mouse specific immunoglobulins. 
The antibodies chosen for the ELISA were tested in the SDS-
PAGE/western blot assays. Both antibodies worked in the non-
immunoprecipitated and immunoprecipitated urine samples, suggesting that the 
mouse anti-mouse antibody and the rabbit anti-human antibody for uPA 
recognize uPA-like protein in the urine and tissues of healthy dogs. The choice of 
a 1:1000 dilution for the rabbit antibody was based on the use of this dilution in 
the Western blot assay. In general the dilution in a Western blot will also work 
well in an ELISA using the same antibodies. 
 One concern in the ELISA assay and the method of concentration used to 
prepare the urine samples is retention of organic salts in the urine samples. 
These salts can interfere with binding of the antibody to the protein resulting in 
the appearance of lower concentration of uPA than is actually present. This may 
have been a problem with our samples. The relationship between the ELISA 
concentrations and the fluorescent concentrations cannot be compared directly; 
however, one would expect that the fluorescent readings would all be lower than 
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the ELISA readings because the fluorescent readings are only measuring active 
uPA. The samples evaluated were consistently lower in the ELISA, once 
corrected for volume and urine creatinine, than the comparable corrected 
fluorescent readings. This would suggest that salts may have a major impact on 
binding in the ELISA assay. 
 Use of a sandwich ELISA allowed us to measure concentration of active 
and inactive urokinase. Again, I am unsure of whether the absolute concentration 
within the samples is accurate. I do believe that the relative concentrations 
between samples are of value as the procedure had less room for operator error 
than the fluorescent assay. The volumes were much larger using 100 µl for each 
sample and a multichanel pipette was used to apply all the antibodies and 
stopping agents. 
 Another issue which may have an impact on determining absolute 
concentrations of uPA in urine for comparison between animals is the question of 
relationship between concentration of urine and uPA. Using creatinine is an 
acceptable method of correcting for concentration when evaluating urea and uric 
acid because the proteins are all excreted in the urine at a constant rate. We do 
not know if uPA and creatinine are excreted in a comparable rate or ratio. Some 
papers do correct for urine concentration using creatinine and express the 
concentration of uPA as a function of mg/ml of creatinine.1, 11 Other papers 
express the concentration of uPA in mg/ml using only a volume correction for 
their calculation.12, 13 This tends to be used more often in healthy subjects or 
when uPA activity is being evaluated as opposed to total concentration. To use 
only a volume correction the assumption must be made that uPA is excreted at a 
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constant rate per milliliter of urine produced. This may be the case in a normal 
healthy person; however, one study has shown that diuresis does decrease the 
uPA concentration in urine.14 This would indicate that, at least in extreme cases 
of diuresis and filtration activity by the kidney, uPA excretion into the urine does 
not match the normal concentration produced per milliliter of urine.14, 15 In the 
case of renal disease the concentration of uPA in excreted urine, as compared to 
healthy people, has been shown to be higher in people with renal disease of 
various types.13 Some other papers suggest that uPA excretion may be 
decreases in renal disease due to increased PAI-1 activity in the kidney.16, 17 
Many of the dogs presented to the Louisiana State University Veterinary 
Teaching Hospital and Clinic are stressed, have had long car rides or may have 
been fasted if they were scheduled for surgery the day they presented. This may 
have affected their normal hydration status and in turn have affected our 
samples. Collecting samples in a more controlled manner would eliminate this 
consideration. This, however, is often not a practical solution when trying to 
obtain large numbers of samples. 
 Statistically there may be a weak correlation between creatinine and uPA 
noted only in female spayed dogs. Whether creatinine is appropriate to use as a 
correction factor for uPA would depend on whether its excretion is proportional to 
that of uPA. Creatinine is excreted at a constant rate in the urine due to muscle 
metabolism. It appears that uPA is excreted in healthy people at a constant rate 
per volume of urine. However, if the same person undergoes diuresis, the 
concentration of uPA per milliliter of urine decreases.14 Obviously in a clinical 
setting these factors would be impossible to control. This is most likely why 
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researchers use creatinine is used to correct for concentration differences 
between samples.    
When evaluating the statistical differences between gender and sexual 
alteration, there is a large amount of overlap between the groups. With the small 
sample numbers we cannot state that there is a significant difference between 
the groups, however, evaluation of the distribution within the scatter plots shows 
evidence of extreme outliers in the male intact and female spayed groups when 
uPA concentration is corrected for creatinine. If we had a larger sample size, this 
may reveal that these points are not actually outliers but the tail of the 
distribution.  
In conclusion, uPA is present in the urine of healthy dogs in very small but 
measurable quantities. It appears to be present in both the active and inactive 
form. At this time, differences in uPA excretion based on gender and sexual 
alteration appear to be not significantly different. This may change as the assays 
are improved and with larger sample sizes. The assays described are not refined 
enough to give accurate concentrations of uPA in the urine. Further work would 
enable both techniques to be useful in a research setting to provide information 
about uPA concentration in urine and possibly even in a clinical setting. 
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Chapter 6 Urokinase and Urokinase Receptor Identification with 
SDS PAGE, Western Blot and Immunoprecipitation 
 
6.1 Introduction 
Proteins in tissues or fluids can be identified by separating them based on 
molecular weight. Proteins can be separated for identification by sodium dodecyl 
(lauryl) sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).1 A molecular 
weight marker and control sample containing the targeted protein allow 
identification of the molecular weight of samples tested in this manner. Migration 
of the proteins through the gel, compared to molecular weight markers and 
controls, identifies the protein. Western Blot allows visualization of a protein band 
based on its recognition by an enzyme-labeled antibody in an ELISA-type 
reaction.2  The protein band is then compared to the molecular weight marker 
and control sample.  
6.2 SDS-PAGE 
Sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis utilizes 
an anionic detergent (SDS) to coat a sample of proteins with uniform negative 
changes to the protein will migrate through a gel towards a cathode. SDS has a 
long hydrophobic tail that binds quantitatively to the hydrophobic side-chains of 
amino acids of proteins.1 SDS binds at a constant ratio of 1.4g of SDS to 1g of 
polypeptide. The larger the molecule, the more SDS binds.  
Proteins possess amino acid chains which are either positively or 
negatively charged. Electrophoresis separates proteins by moving them across a 
gel towards a positive charge. The SDS has a high negative charge giving 
proteins within a sample an equal negative charge.1 
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Protein tertiary structure also influences migration through a gel. If two 
proteins have equal mass, the protein with a more linear structure will traverse 
the gel more slowly due to the greater resistance offered by its length. Protein 
tertiary structure is formed by the opposing electrical charges on the amino acid 
chains. Binding of SDS to the amino acid chains removes the opposing electrical 
charges resulting in unfolding of the protein. 2-mercaptoethanol or dithiothreitol 
added to the SDS causes disruption of disulphide bonds which also hold the 
protein in its native physical form. Removal of both electrostatic and the disulfide 
bonds from a protein sample results in all proteins within the sample becoming 
uniformly linear and movement through the gel.1  
Polyacrylamide gel is a semisolid matrix of acrylamide chains cross-linked 
to create a porous gel. The percent of acrylamide used depends on the size of 
the protein being identified. The porosity of that gel is determined by the length of 
the acrylamide chains and the degree of cross-linking. The length of the 
acrylamide chains is determined by the concentration of acrylamide in the 
polymerization reaction used to make the gel (3.5%-20%). The more 
concentrated the acrylamide, the longer the resulting acrylamide chains and the 
denser the gel. The denser the gel the more difficult it is for larger proteins to 
move though.3 A 7.5% acrylamide gel was selected for identification of uPA since 
uPA is relatively small molecule and a previous study had shown success with 
this concentration of acrylamide. 4  Other experiments used a 10% acrylamide gel 
for identification of both uPA and uPAR.5, 6 
A gel can be set up as continuous or discontinuous (figure 6.1). Use of 
different buffers is required to create the gel and to fill the running tank. A 
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continuous system has only one separating gel and uses the same buffer in the 
tank and the gel. We used a discontinuous system with a large pore non-
restrictive gel (stacking gel) layered on top of a separating gel (resolving gel). 
The discontinuous system has superior resolution for protein separation and 
visualization of protein bands over the continuous system.1 
 
Figure 6.1 SDS-PAGE gels, continuous and discontinuous arrangement 
6.3 Western Blot  
Western Blot (a.k.a. immunoblot) identifies a protein from a mixture of 
proteins based on a specific antigenicity towards a known antibody in an ELISA-
type reaction. This also identifies the molecular weight of the protein as 
compared to the visual molecular weight marker because it allows visualization of 
the protein band.2 The protein bands separated using SDS-PAGE are transferred 
to a solid membrane (nitrocellulose or polyvinylidene) via an electric current 
applied across the gel and membrane (figure 6.2). The current moves the 
separated negatively charged proteins through the gel, onto the membrane. The 
membrane is the medium for the ELISA-type reaction.7 Following transfer the 
membrane is non-specifically blocked with a protein solution to prevent sites 
which do not contain the targeted blotted protein from binding with antibody. This 
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non-specific binding would give false positive results and/or cause background 
reaction.  
The membrane, with the transferred proteins, is incubated in a solution 
containing a primary antibody towards the targeted protein.7 The solution of 
primary antibody also contains a protein solution such as non-fat dried milk, 
casein or bovine serum albumin. If the targeted protein is on the membrane the 
primary antibody in the solution will bind with that protein. Following incubation 
with the primary antibody, unbound antibody is washed away and a secondary 
antibody labeled with an enzymatic marker is added to the membrane. This 
secondary antibody is directed towards the species the primary antibody was 
raised in, creating a sandwich type effect. The reaction is visualized by adding a 
substrate to the enzyme marker on the secondary antibody. This may be a color 
reaction or a chemiluminescent reaction depending on the substrate (figure 6.3).7 
 
Figure 6.2 Transfer of proteins from SDS-PAGE gel to polyvinylidene membrane. 
 79
 
Figure 6.3 Western Blotting Procedure for uPA and uPAR in canine urine and tissue. 
 
6.4 SDS-PAGE and Western Blot for Urokinase and Urokinase Receptor 
6.4.1 Samples 
Pooled fresh frozen kidney, testicle and prostate and concentrated frozen 
urine from healthy dogs were examined. Samples of urine were chosen at 
random from the 54 urine samples collected (Chapter 4, Sample Selection and 
Preparation). Samples selected were from Male intact #7 and #4 and female 
spayed #9 and #7 and an unknown urine sample. 
Tissue samples were manually crushed using a Dounce tissue grinder. 
Samples were suspended in RIPA buffer (MFCD2100484, Sigma-Aldrich, St. 
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Louis, MO) at 4ºC until a homogenous substance remained. The supernatant 
was then transferred to polypropylene screw cap micro tubes (72.694, Sarstedt 
AG & Co., Newton, NC) and frozen at -20 ºC for later analysis then thawed prior 
to SDS-PAGE. Previously concentrated urine that was frozen in 1.5ml 
microcentrifuge tubes (20170.022, VWR International, Suwanee, GA) was 
thawed at room temperature prior protein separation by SDS-PAGE.  
6.4.2 Antibodies, Purified Enzymes and Buffers 
• Monoclonal Antibody against Mouse uPA – A capture monoclonal 
antibody produced in a uPA knockout mouse. IgG fraction purified by 
Protein A Sepharose. (H77A10, Molecular Innovations, Southfield, MI) 
• Monoclonal antibody against human urokinase B-chain – A murine IgG1 
monoclonal antibody directed against a B-chain epitope of human 
urokinase, near the catalytic site. Reacts with free and receptor bound, 
single and two chain (HMW) urokinase and the B-chain (33kDa) fragment. 
(3689, American Diagnostica Inc., Stamford, CT) 
• Rabbit anti-human uPA IgG fraction, biotin labeled – Biotin labeled 
polyclonal antibody (host rabbit). IgG fraction purified by protein A 
sepharose. (ASHUPA-GF-BIO, Molecular Innovations, Southfield, MI) 
• Monoclonal antibody against human uPA receptor (CD 87) – A murine 
monoclonal antibody, subclass IgG2a, recognizing the human urokinase 
receptor. It binds with both unoccupied and occupied uPAR, to soluble 
uPAR and intracellular uPAR of both normal blood cells and tumor cells. 
(3936, American Diagnostica Inc., Stamford, CT) 
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• Peroxidase conjugated Affinity-purified Anti-Mouse IgG (H&L) (Goat) (Min 
X Human Serum Proteins). (611-1322, Rockland Immunochemicals Inc., 
Philadelphia, PN) 
• Peroxidase conjugated Affinity purified Anti-Rabbit IgG (H&L) (Goat) (Min 
X Human Serum Proteins). (611-1322, Rockland Immunochemicals Inc., 
Philadelphia, PN) 
• Active Mouse Urokinase, HMW – Active two-chain HMW mouse 
urokinase, recombinant produced in insect cells. (MUPA, Molecular 
Innovations, Southfield, MI) 
• Human HMW Urokinase – Prepared from human urine as the two-chain 
form. (UPA-HTC, Molecular Innovations, Southfield, MI) 
• Lower Gel Buffer – 181.7g Tris, 5.0g SDS to 750ml distilled water, adjust 
pH to 8.8 with concentrated HCl, then bring to 1000ml. Refrigerated. 
• Upper Gel Buffer – 30.3g Tris, 2.0g SDS to 350ml distilled water, adjust 
pH to 6.8 with concentrated HCl, then bring to 500ml. Refrigerated. 
• SDS Running Buffer – 60.6g Tris, 288.0g Glycine, SDS 20.0g in 2 liters of 
distilled water. Store at room temperature. Diluted 1:10 with distilled water 
before using. 
• Tris Buffered Saline (TBS) – 10 mM Tris pH 7.5, 150 mM NaCl in 1000 ml 
distilled water. 
• Western Transfer Buffer – 0.2g SDS, 5.8g Tris, 2.8g Glycine, 150ml 
MeOH, 850ml distilled water. Refrigerate. 
• Stacking Gel – 1.25ml upper gel buffer, 2.95 ml distilled water, 0.8ml of 
30% acrylamide(EM Science, Darmstadt, Germany) , 15µl 10% 
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Ammonium Persulfate (17874, Pierce Chemicals, Rockford, IL), 5µl TMED 
(17919, Pierce Chemicals, Rockford, IL) 
• 7.5% SDS PAGE Resolving Gel – 8ml lower gel buffer, 13.25ml distilled 
water, 10.5ml 30% acrylamide (EM Science, Darmstadt, Germany), 50µl 
10% Ammonium Persulfate (17874, Pierce Chemicals, Rockford, IL), 25µl 
TMED (17919, Pierce Chemicals, Rockford, IL) 
6.4.3 SDS PAGE Procedure 
The SDS-PAGE gel and buffers were prepared as described above in 
quantities sufficient to create to gels in a BioRad Minigel II apparatus (170-3056, 
Bio-Rad, Hercules, CA). This is consistent with the procedure described by 
Laemelli. 8 Protein in both tissue and urine samples were denatured by boiling at 
100ºC. Four microliters of 4X SDS Sample Buffer (70607, Novagen, Madison, 
WI) was added to 20 µl of denatured sample and applied to the SDS gel (10cm 
resolving gels of 7.5% acrylamide and 2cm stacking gels of 4% acrylamide). The 
samples were subjected to electrophoresis at room temperature at 100mV for 2 
hours or until the dye reached the bottom of the gel. Perfect Protein™ HRP 
Western Blot (69078-3, Novagen, Madison, WI) molecular weight marker or 
Rainbow Markers (RPN800, Amersham Biosciences, Buckinghamshire, England) 
molecular weight marker, were run in the first lane beside the samples to enable 
identification of the molecular weight of each protein band.  
6.4.4 Western Blot Procedure 
Separated proteins were transferred from the SDS gel to Polyvinylidene 
Fluoride membranes (BioTrace PVDF, 66543, Pall Corporation, Pensacola, FL) 
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for Western Blot analysis using western transfer buffer. Protein transfer was 
performed in a Bio Rad Mini Gel Transfer (170-3056, Bio-Rad, Hercules, CA) 
western blot apparatus over one hour at 100mV. The polyvinylidene membrane 
was then incubated with the primary antibody at 1:1000 dilutions in a 4% non-fat 
dry milk powder reconstituted in TBS solution for 16 hours at 4ºC. For detection 
of urokinase we used mouse anti-mouse uPA (H77A10, Molecular Innovations), 
mouse anti-human uPA (3689, American Diagnostica Inc.) and rabbit anti-human 
uPA (ASHUPA-GF-BIO, Molecular Innovations) as the primary antibodies. For 
urokinase receptor detection we used a mouse anti-human uPAR antibody 
(3936, American Diagnostica Inc.) as the primary antibody.  
The following morning the membrane was washed 3 times, (30 minutes 
each), with the 4% non-fat skim milk solution at room temperature. Following 
washing, the membrane was incubated at room temperature for 2 hours, with a 
secondary antibody (goat-anti-mouse or goat-anti-rabbit dependant on the 
species in which the primary antibody was raised) labeled with a 
chemiluminescent tag at a 1:5000 dilution. The membrane was again washed 3 
times (30 minutes each) with a 1% non-fat dry milk solution. The results were 
visualized using Western Lightning Chemiluminescence Reagent (NEL101, 
PerkinElmer Life Sciences, Boston, MA) on Fuji Medical X-ray film, Super RX 
(91454, Tokyo, Japan). 
6.4.5 Problems 
Two main problems were encountered during our SDS-PAGE and 
Western Blot experiments. The first was non-specific binding of antibody to the 
polyvinylidene membrane causing high background (dark background 
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precipitation) at the time of development of the films. This was resolved by using 
a lower primary antibody concentration at 1:1000 and secondary antibody 
concentration at 1:5000 which lowered the non-specific binding. The membrane 
was blocked with the 4% casein solution between the first and second antibody 
incubations for three 45 minute applications. This blocking also aided in 
prevention of non-specific binding to the polyvinylidene membrane. Use of film 
specifically intended for Western Blot analysis also reduced in background. 
The second problem was faint or absent signal in our test lanes for 
concentrated urine samples and testicle and prostate samples. This was 
postulated to be due to low concentrations of uPA in the samples and was 
resolved by using immunoprecipitation of the sample prior to SDS-PAGE.  
6.5 Immunoprecipitation 
Immunoprecipitation is the interaction between a protein and a specific 
antibody which allows the proteins to be removed from solution and examined for 
quantity or physical characteristics such as molecular weight or isoelectric point.9 
Antibody-protein complexes are removed from solution by adding an insoluble 
form of an antibody binding protein such as Protein A, Protein G or combination 
Protein A/G, rather than depending on spontaneous formation of insoluble 
antigen-antibody complexes. This makes determination of an optimal antibody 
dilution favoring spontaneously occurring immunoprecipitates unnecessary. 
Analysis of the immunoprecipitate is usually via electrophoresis.9 The 
choice of immobilized antibody binding protein depends on the species the 
primary antibody was raised in. The strength of the interaction between a 
monoclonal antibody and Protein G or Protein A is important factor in the 
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decision of which to use. These interactions have been evaluated and published. 
The success of immunoprecipitation depends on the affinity of the primary 
antibody for the targeted protein as well as for Protein A or Protein G. In this 
study a combination Sepharose bead with both Protein A and Protein G was 
used. 
The simplified procedure is as follows9 (figure 6.4): 
 
 
Figure 6.4 Immunoprecipitation of uPA or uPAR using Protein G/A Sepharose beads 
 
1. An antibody is added to a mixture of proteins which binds specifically 
to the targeted protein during an incubation period.  
2. The antigen-antibody complex is absorbed from the solution through 
addition of an immobilized antibody binding protein such as Protein A-
Sepharose beads and this solution is incubated. 
3. The solution is centrifuged and the antigen-antibody complex settles to 
the bottom of the tube, attached to the Sepharose beads, in the form of 
a pellet. 
4. The supernatant is removed from the tube, leaving the pellet behind.  
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5. Liberation of the targeted protein can be achieved by boiling the pellet 
in the presence of SDS. This destroys the bond between the primary 
antibody and the protein, freeing the denatured protein. 
6.5.1 Samples 
For immunoprecipitation 200µm of pooled fresh frozen kidney, testicle and 
prostate and concentrated frozen urine from healthy dogs were examined. 
Samples of urine were chosen at random from the 54 urine samples previously 
collected (Chapter 2, Sample Selection and Preparation. Samples selected were 
from female spayed #7 and an unmarked urine sample. 
6.5.2 Immunoprecipitation Procedure 
Both tissue and urine samples were incubated with or without 2µm of anti-
human uPA antibody at room temperature for 2 hours. Samples without antibody 
were used as controls. For uPA detection we used mouse anti-mouse uPA 
(H77A10, Molecular Innovations) and mouse anti-human uPA (3689, American 
Diagnostica Inc.). For urokinase receptor detection we used a mouse anti-human 
uPAR antibody (3936, American Diagnostica Inc.).  
The antibody complexes were precipitated by adding Protein G 
PLUS/Protein A-Agarose Sepharose beads (IP05, Calbiochem, San Diego, CA) 
and incubating for 1 hour at room temperature. The beads were washed 3 times 
using Tris Buffered Saline at 4 ºC  and the antibody-protein complexes were 
separated from each other and the Sepharose beads by boiling at 100 ºC  for 3 
minutes. The resulting solution containing the targeted protein was separated 
using SDS PAGE and evaluated using the western blot technique as described 
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previously. Negative controls contained the antibody alone without the tissue 
lysate. Perfect Protein™ HRP Western Blot (69078-3, Novagen, Madison, WI) 
molecular weight marker or Rainbow Markers (RPN800, Amersham Biosciences, 
Buckinghamshire, England) molecular weight marker, was run in the first lane 
beside the samples to enable identification of the molecular weight of each 
protein band.  
6.6 Results 
6.6.1 Urokinase without Immunoprecipitation 
 All samples were evaluated for molecular weight by comparing the 
generated proteins bands with Perfect Protein™ HRP Western Blot (69078-3, 
Novagen, Madison, WI) molecular weight marker or Rainbow Markers (RPN800, 
Amersham Biosciences, Buckinghamshire, England) molecular weight marker, 
which was run in the first lane beside the samples. Negative controls contained 
lanes without the targeted antigen. Incubation of kidney tissue lysate with both 
the mouse anti-mouse antibody and the mouse anti-human antibody produced a 
strong band at approximately 50kDa molecular weight (figure 6.5). A second 
western blot evaluating the testicle, prostate and kidney lysates demonstrated a 
band at approximately 50 kDa and at 30 kDa. The sample was run with a pure 
sample of uPA, with known high molecular weight and low molecular weight 
forms of uPA in the purified enzyme, which produced bands at the same 
molecular weight as the tissue proteins (figure 6.6) 
6.6.2 Urokinase Receptor without Immunoprecipitation 
 All samples were evaluated for molecular weight by comparing the 
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Figure 6.5 Western Blot showing urokinase bands at approximately 50 kDa molecular weight. 
Samples are of concentrated urine from healthy dogs. PP, Perfect Protein™ HRP Western Blot 
(69078-3, Novagen) molecular weight marker; MI, mouse anti-mouse uPA (H77A10, Molecular 
Innovations); AD, mouse anti-human uPA (3689, American Diagnostica Inc); #7, unk, F, random 
urine samples; kDa, molecular weight in kilodaltons. 
 
 
Figure 6.6 Western Blot showing urokinase bands at approximately 50 and 30 kDa molecular 
weight. (Rainbow Markers) Samples were run with a known control of pure human urokinase 
which contains high molecular-weight uPA and low molecular-weight uPA. Samples are from 
desiccated prostate, kidney and testicle from a male intact dog (Male #4). kDa, molecular weight 
in kilodaltons. 
 
generated proteins bands with Rainbow Markers (RPN800, Amersham 
Biosciences, Buckinghamshire, England) molecular weight marker which was run 
in the first lane beside the samples. The samples evaluated were from 
desiccated prostate, kidney and testicle from the tissue sample group, male dog 
# 4 (appendix table 8). Boiled prostate, kidney and testicle samples incubated 
with the mouse anti-human uPAR antibody generated 2 protein bands. One band 
is at approximately 55 kDa, which is quite light, and another darker band at 
approximately 35 kDa (figure 6.7).   
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Figure 6.7 Western Blot showing uPAR protein bands at 55 kDa and 35 kDa. (Rainbow Markers) 
Samples were run in SDS-PAGE on the same gel as figure 6 which contains a known control of 
pure human urokinase. Samples are from desiccated prostate, kidney and testicle from a male 
intact dog (Male #4). kDa, molecular weight in kilodaltons. 
6.6.3 Urokinase with Immunoprecipitation 
 All samples were evaluated for molecular weight by comparing the 
generated proteins bands with Perfect Protein™ HRP Western Blot (69078-3, 
Novagen, Madison, WI) molecular weight marker or Rainbow Markers (RPN800, 
Amersham Biosciences, Buckinghamshire, England) molecular weight marker, 
which was run in the first lane beside the samples. Negative control lanes 
contained solution without the antibody. Boiled testicle, prostate and kidney 
lysates incubated with the mouse anti-mouse and the rabbit anti-human 
urokinase antibodies produced strong bands at approximately 50kDa and 33kDa. 
Boiled concentrated urine and unconcentrated urine incubated with the mouse 
anti-mouse, the mouse anti-human urokinase, and the rabbit anti-human 
antibodies produced strong bands at approximately 50kDa and 33kDa (figures 
6.8 and 6.9).  
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Figure 6.8 Western Blot showing immunoprecipitated uPA protein bands at 50kDa and 30 kDa 
molecular weights as compared to the perfect protein molecular weight marker using the mouse 
anti-mouse uPA antibody (H77A10, Molecular Innovations) as the primary antibody. MWM, 
Perfect Protein™ HRP Western Blot (69078-3, Novagen) molecular weight marker; Urine, 
concentrated samples; Straight, unconcentrated sample; Ab, antibody used to immunoprecipitate 




Figure 6.9 Western Blot showing immunoprecipitated uPA bands at 50 kDa and 35 kDa using the 
rabbit anti-human uPA antibody. kDa, molecular weight in kilodaltons. 
 
6.6.4 Urokinase Receptor with Immunoprecipitation 
 All samples were evaluated for molecular weight by comparing the 
generated proteins bands with Rainbow Markers (RPN800, Amersham 
Biosciences, Buckinghamshire, England) molecular weight marker which was run 
in the first lane beside the samples. Immunoprecipitated boiled kidney, testicle 
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and prostate lysates incubated with mouse anti-human urokinase receptor 
antibody produced strong bands at approximately 60kDa (figure 6.10). 
 
 
Figure 6.10 Western Blot showing immunoprecipitated uPAR bands at 60 kDa, as compared to 




 We have identified proteins in the tissues and urine of healthy dogs, with 
antibodies directed against human and mouse uPA and human uPAR. The uPA 
antibodies detected a protein in the urine, kidney, prostate and testicle from 
healthy dogs which is the same molecular weight as uPA in both the high 
molecular weight form (53 kDa) and the low molecular weight form (33 kDa). A 
high molecular weight band for uPA is expected at approximately 50 kDa and the 
low molecular weight band is generally at approximately 30 kDa.10, 11 In the 
western blots run with pure uPA as a control, the proteins bands were present at 
the same molecular weight as the pure uPA which further supports that the 
bands we identified are high and low molecular weight uPA. The uPAR antibody 
detected a protein in immunoprecipitated kidney, testicle and prostate from 
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healthy dogs which is the same molecular weight as uPAR. The band at 55 kDa 
is within the reported reference range for uPA at 55-60 kDa.12, 13 
This would provide evidence that urokinase and urokinase receptor-like 
proteins are present in the urinary tract and urine of healthy dogs. This also 
suggests that antibodies against mouse and human uPA and human uPAR can 
be used to detect these proteins in the dog. The results from our Western Blot 
analysis with the mouse anti-mouse uPA antibody were also duplicated at the 
Molecular Innovations laboratory in Southfield Michigan.  
Immunoprecipitation was used to concentrate uPA from urine, testicle, 
prostate and kidney. Immunoprecipitation was also used to concentrate uPAR in 
kidney, testicle and prostate samples. The uPA-like concentration in the urine of 
healthy dogs appears to be low. Western blot without immunoprecipitation 
resulted in very faint or no bands. Immunoprecipitation enhanced visualization of 
bands for uPA in concentrated and unconcentrated urine. These findings suggest 
that uPA is present in urine but in small quantities.  
Immunoprecipitation was not as necessary in the tissue samples. Kidney 
samples produced consistently strong bands in the western blot analysis. 
Prostate and testicle produced bands, but they were often much weaker and the 
immunoprecipitation enhanced the visualization of the bands. 
We did not measure the weight of the kidney, prostate and testicle tissues 
prior to desiccation therefore we cannot compare the intensities of the bands in a 
single Western blot to quantify the amount of uPA and uPAR within the samples. 
Western blots are at best semiquantitative and a better method of comparing 
protein concentrations would be in an ELISA or activity assay such as the 
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fluorescence assay discussed in Chapter 5, Fluorogenic and ELISA Assays for 
Urokinase in Urine. 
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Chapter 7 Localization of Urokinase and Urokinase Receptor 
Using Immunohistochemistry 
 
7.1 Immunohistochemistry Introduction 
Immunohistochemistry is the localization of antigens in tissue sections 
through antigen-antibody interactions that are visualized microscopically via a 
marker such as fluorescent dye, enzyme, radioactive element or colloidal gold.1, 2 
Immunohistochemistry identifies the distribution of specific cellular components 
within a cell or tissue. The term immunohistochemistry is used interchangeably 
with immunocytochemistry and immunostaining. 
Immunohistochemistry is an ELISA reaction, in which a primary antibody 
is applied to the tissue with a secondary, labeled-antibody then applied to detect 
the bound primary antibody.1, 2 A typical immunohistochemical protocol involves: 
1. Fixation of the tissue - Fresh frozen tissue can be used and for 
some antigens, is required. Although frozen tissues have the best 
antigen preservation they are more difficult to work with and 
preservation of tissue architecture is poor.2, 3 Tissues preserved in a 
fixative of commonly formalin is preferred and provides better 
preservation of tissue architecture with “minimal” loss of tissue 
antigenicity. 1, 3 Fixed tissues are then embedded in paraffin for 
sectioning. Paraffin embedding may cause some shrinkage or 
distortion, but will preserve the tissue architecture.3 Other fixation 
solutions include mercuric chloride-based fixatives, which cause 
minimum distortion but have poor tissue penetration, and acetone, 
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which has excellent antigen preservation but very poor tissue 
preservation. Acetone is preferred for cell smears.3 
2. Antigen retrieval - Fixation and embedding can cause antigen 
masking.2, 4  Some epitopes are formalin sensitive and undergo 
substantial change.4 Other epitopes are formalin-resistant and 
remain unchanged. Cross-linking of unrelated proteins to the target 
antigen is also possible. Both enzymatic and heat-mediated antigen 
retrieval are used to overcome antigen loss. 2, 4  Enzymatic retrieval 
can be used alone or in combination with heat-induced antigen 
retrieval. Enzymatic or proteolytic retrieval works by etching the 
tissue and allowing hidden determinants to be exposed. Enzymes 
used include chymotrypsin and pepsin.  Digestion procedures are 
often combined with heating by microwave or pressure-cooking to 
enhance retrieval of antigens. The energy from the heating is 
believed to break some of the bonds formed during fixation. 
Tissues to be heat treated may be immersed in retrieval solutions 
such as citrate prior to processing. 
3. Endogenous enzyme block – All hemoproteins contain endogenous 
peroxidase activity which results in increased background staining 
on immunohistochemistry slides. Peroxidase activity can be 
suppressed by incubating formalin fixed tissues in 3% H2O2 prior to 
beginning staining. This is especially important in red blood cells, 
leukocytes, muscle, liver and kidney.5  
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4. Avidin-biotin block – Biotin is present in many tissues including the 
liver, mammary gland, adipose tissue and kidney and can result in 
false positive staining, falsely indicating the presence of an antigen. 
Avidin or streptavidin are commonly used as blocking agents which 
suppress endogenous biotin by binding the biotin with the avidin or 
streptavidin making the biotin unavailable for binding with 
antibodies used in the immunohistochemical stain. 5 
5. Blocking nonspecific sites – Blocking reactive sites in tissues is 
important for an immunohistochemical reaction. Non-immune 
serum from the host species of the secondary antibody is applied to 
the tissue at the beginning of the procedure. The serum adheres to 
the protein-binding sites by nonspecific adsorption or by binding of 
specific, but unwanted, serum antibodies to antigens in the tissue.1 
6. Incubation with primary antibody – The primary antibody may be 
directly labeled with a detection enzyme (horseradish peroxidase) 
or fluorophore (Fluorescein) or unlabeled, allowing detection with a 
labeled secondary antibody. Choice of primary antibody depends 
on the antigen of interest. Homology between species within an 
antigen allows use of antibodies from other species. Choice of a 
monoclonal or polyclonal antibody is also important and again 
depends on the species of interest and the target antigen. Dilutions 
for each antibody and tissue must be optimized for the system 
being used. The optimal dilution gives the strongest specific antigen 
staining with the lowest non-specific background.1, 2 
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7. Incubation with a secondary antibody-enzyme conjugate – If a 
system using a secondary antibody is selected, the secondary 
antibody is labeled with either an enzymatic or fluorescent label. 
The secondary antibody is generated against the immunoglobulins 
of the primary antibody source. For example, if the primary antibody 
is raised in a mouse, the secondary antibody could be goat anti-
mouse. Dilutions for the secondary antibody must also be optimized 
for the system being used.1, 2  Methods to amplify the signal include 
biotinylated compounds such as in the ABC procedure and chain 
polymer-conjugated technology such as with the biotin free 
EnVision™ system.2, 6 
8. Enzyme-mediated detection – Enzymatic color change or 
fluorescence is required to visualize the final ELISA reaction in the 
tissue. Horseradish peroxidase is commonly used and will react 
with a chromogenic substrate to cause a color change. The color 
change depends on the chromogen chosen.7 
9. Controls – Negative tissue controls must be processed identically to 
the tissue being investigated and should not contain the relevant 
tissue marker. Positive tissue controls must be processed 
identically to the tissue being investigated and must contain the 
target protein. Internal tissue controls contain the target antigen of 
the tissues being investigated and also in adjacent normal tissue as 
is the case with many tumor samples which contain normal and 
affected tissue.8 
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Stained tissues can be described based on subjective evaluation of the 
staining intensity within the tissue and specific cell types. Stained tissue can also 
be assessed semi-quantitatively using software that codes specific intensities. 
7.2 Immunohistochemistry for Urokinase and Urokinase Receptor 
Detection 
7.2.1 Samples 
Tissue samples were harvested and processed as described in Chapter 4, 
Sample Selection and Preparation. Slides cut from the same tissue block were 
used for both the urokinase and urokinase receptor immunohistochemistry.  
7.2.2 Antibodies  
• Mouse Monoclonal to mouse uPA – A capture monoclonal antibody 
produced in a uPA knockout mouse. IgG fraction purified by Protein A 
Sepharose. (H77A10, Molecular Innovations, Southfield, MI) 
• Monoclonal antibody against human urokinase B-chain – A murine IgG1 
monoclonal antibody directed against a B-chain epitope of human 
urokinase, near the catalytic site. Reacts with free and receptor bound, 
single and two chain (HMW) urokinase and the B-chain (33kDa) fragment. 
(3689, American Diagnostica Inc., Stanford, CT) 
• Monoclonal antibody against human uPA receptor (CD 87) – A murine 
monoclonal antibody, subclass IgG2a, recognizing the human urokinase 
receptor. It binds with both unoccupied and occupied uPAR, to soluble 
uPAR and to uPAR inside both normal blood cells and tumor cells. (3936, 
American Diagnostica Inc., Stanford, CT) 
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7.2.3 Immunohistochemistry Technique for Urokinase Detection 
 
 
Figure 7.1 Schematic of the two step EnVision System for uPA detection in canine tissue 
sections. The dextran chain allows for multiple sites of secondary antibody and enzyme 
attachment to the primary antibody. This results in signal amplification. 
 
All immunohistochemical studies were performed on paraffin embedded 
sections (4µm). For urokinase detection, endogenous enzyme block was 
performed using 0.3% hydrogen peroxide for 10 minutes. Sections were then 
treated with Proteinase K for 2 minutes for enzyme retrieval followed by protein 
block with horse serum for 30 minutes. The sections were incubated for 30 
minutes with Primary mouse anti-mouse uPA antibody at 1:200 dilutions. The 
primary antibody was omitted for negative controls. The secondary antibody 
system used the mouse EnVision™ system, which uses a biotin free chain 
polymer-conjugated technology with horseradish peroxidase as the enzyme. This 
incubation was performed for 30 minutes. The sections were then incubated for 8 
minutes with the chromogen NovaRed to allow visualization of the antigen-
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antibody complexes (figure 7.1). Slides were counterstained with hematoxylin for 
5 minutes. Intensity of staining was subjectively evaluated by one investigator. 
Cell types staining were identified and described. 
7.2.4 Immunohistochemistry Technique for Urokinase Receptor  
Detection 
 
For urokinase receptor detection endogenous, enzyme block was 
performed using 0.3% hydrogen peroxide for 10 minutes. Sections were then 
treated with high pH TRS for 2 minutes for enzyme retrieval followed by protein 
block with horse serum for 30 minutes. The sections were incubated for 60 
minutes the with primary antibody mouse anti-human uPAR at a 1:100 dilution. 
The secondary antibody system used the mouse EnVision™ system, which uses 
a biotin free chain polymer-conjugated technology with horseradish peroxidase 
as the enzyme. The sections were then incubated for 8 minutes with the 
chromogen NovaRed to allow visualization of the antigen-antibody complexes. 
Slides were counterstained with hematoxylin for 5 minutes. Intensity of staining 
was subjectively evaluated by one investigator. Cell types staining were identified 
and described. 
7.3 Problems 
The antibody chosen for our tissue samples was the mouse anti-mouse 
monoclonal antibody from Innovative Research which is produced using 
urokinase knock-out mice. Our immunohistochemistry protocol was based on the 
protocol from Innovative Research. One problem was over digestion of the 
tissues by the enzymatic antigen retrieval system. This was especially 
problematic with the testicular and prostate tissue. Use of a 1:2 dilution protocol 
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for the Proteinase K solved this problem. Increased background was also an 
issue due to known endogenous biotin in the kidney. This was overcome by 
using an EnVision system which uses a biotin free chain polymer-conjugated 
technology as the secondary antibody system. 
Another problem encountered was with orientation of the tissue samples 
for mounting. In some of the urinary bladder, urethra and ureter samples the 
tissues required reorientation with the paraffin blocks to allow cross sections 
which contained mucosa. This could have been prevented by more careful 
examination of each tissue sample at the time of embedding. Smudging of some 
of the mucosal borders was also evident. This can be prevented by fixing the 
samples prior to cutting for paraffin embedding. Freezing of the samples may 
have contributed to loss of some of the mucosal edges as well making the 
mucosal lining more susceptible to damage when being placed in the cassettes 
for paraffin embedding. Urokinase and urokinase receptor epitopes in canine 
tissue do not appear to be masked direct fixation in formalin, so this technique is 
acceptable. Formalin fixation provides good preservation of architecture. 
7.4 Results 
 All organs in the urinary tract showed evidence of staining for urokinase 
and most tissues were positive for urokinase receptor. Other supporting tissues 
such as smooth muscle, skeletal muscle, vascular endothelial cells and 
leukocytes also showed evidence of staining for urokinase and urokinase 
receptor (appendix tables 4, 5, 6, 7, 8 and 9). 
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7.4.1 Urokinase and Kidney  
 
Figure 7.2 Immunohistochemical staining of uPA within kidney. (100X magnification) Staining is 
noted in the cytoplasm of the epithelial cells lining the renal tubules. Some plasma staining is 
noted within the glomeruli. 
 
Staining in the kidney was consistent was consistent for male and female dogs 
and for castrated and intact male dogs (appendix table 4) Staining was red to 
red-brown and uniform in the cytoplasm of the cells. There was intense staining 
in tubular epithelial cells throughout the cortex and medulla of the kidney. In 
some samples cells in the medullary tubules stained slightly more intensely than 
cells in the proximal convoluted tubules. Staining was evident in the endothelial 
cells of the glomeruli in some kidneys. Inflammatory cells and endothelial cells of 
both arteries and veins also stained (figure 7.2). Staining was evident in the 
mucosa of the renal pelvis within the cytoplasm of the luminal cells in the 
transitional epithelium. Staining of the transitional epithelium was segmental. The 
renal pelvis that was involuted stained uniformly throughout the cytoplasm of the 
entire layer of cells. The renal pelvis which protruded into the pelvis stained along 




Figure 7.3 Immunohistochemical staining of uPA within the transitional epithelium of the renal 
pelvis. (100X magnification) Staining of cytoplasm of the transitional epithelial cells is present. 
Staining is more intense in the luminal cells and is segmental. Staining of the cytoplasm of 
endothelial cells of veins and inflammatory cells within the renal parenchyma is visible.  
7.4.2 Urokinase Receptor and Kidney 
 Staining in the kidney was consistent was consistent for male and female 
dogs and for castrated and intact male dogs (appendix table 4). Staining was red 
to red-brown and appeared more granular than the urokinase staining. Intense 
granular staining was noted in cytoplasm of inflammatory cells in the parenchyma 
and in the blood vessels. Granular staining was present along the basement 
membranes of the epithelial cells in both proximal and medullary tubules (figure 
7.4). The mucosa in the renal pelvis showed granular staining along the surface 
and within cytoplasm of the luminal cells of the transitional epithelium. 
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Figure 7.4 Immunohistochemical staining of uPAR in the kidney. (0000 magnification) Granular 
staining along the basement membrane of tubular epithelial cells. Slight cytoplasmic staining of 
these tubular cells is also evident. 
 
7.4.3 Urokinase and Ureter 
 There was intense and uniform staining of the transitional epithelium of the 
ureter in all dogs evaluated (appendix table 5). Staining was along the luminal 
cell membrane of the surface epithelial cells and within the cytoplasm throughout 
all layers of transitional epithelial cells of the mucosal lining. The cytoplasm of 
inflammatory cells within the connective tissue of the ureter wall and vascular 
endothelial cells were stained (figure 7.5). 
7.4.4 Urokinase Receptor and Ureter 
 There was granular staining was noted along the membrane of the luminal 
cells at the surface of the transitional epithelium lining the ureter in all dogs 
evaluated (appendix table 5). Granular cytoplasmic staining was noted in the first 
and sometimes second layer of cells. Inflammatory cells stained positive. No 
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Figure 7.5 Immunohistochemical staining of uPA in the ureter. Membrane staining is noted along 
the luminal surface of the cells in the transitional epithelium. The cytoplasm of all cells in the 
transitional epithelium is staining. Also staining are the inflammatory cells in the connective tissue 




Figure 7.6 Immunohistochemical staining of uPAR in the ureter. Granular membrane staining is 
noted along the luminal surface of the cells in the transitional epithelium. The cytoplasm of cells in 
the first two cells layer in the epithelium is staining. Also staining are the inflammatory cells in the 
connective tissue of the ureter wall 
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staining was noted in the deeper cells of the transitional epithelium. Inflammatory 
cells within the connective tissue of the ureter wall were stained (figure 7.6). 
7.4.5 Urokinase and Urinary Bladder 
 There was staining of the transitional epithelium on the urinary bladder in 
all dogs evaluated (appendix table 6). Staining was variable with some sections 
of the mucosa stained throughout all cell layers on the luminal membrane surface 
and within the cytoplasm. Other sections only showed staining on the surface 
layer or not at all. The sections which had staining appear invaginated and there 
was increased vacuolization of the cytoplasm. Other cells which stained positive 
were the smooth muscle cells and skeletal muscle cells, endothelial cells of 
vessels and inflammatory cells within the bladder wall. These cells all stained in 
the cytoplasm. Two of the urinary bladder sections showed inflammation 
consistent with chronic cystitis. These samples displayed intense urokinase 
staining along the mucosa in the same regions as the normal bladder (figure 7.7) 
7.4.6 Urokinase Receptor and Urinary Bladder 
 Granular staining was noted along the luminal surface membrane of the 
cells in the transitional epithelium in all dogs evaluated (appendix table 6). 
Granular cytoplasmic staining of the cells in the transitional epithelium was 
evident in some regions extending only to the first one to two layers of cells. 
Inflammatory cells within the wall stained consistently (figure 7.8). 
7.4.7 Urokinase and Prostate 
 Staining in the prostate was highly variable (appendix table 8). Male 1 




Figure 7.7 Immunohistochemical staining of uPA in the urinary bladder. Staining is noted in the 
cytoplasm of cells in the transitional epithelium in the invaginated section. These cells are also 
more vacuolated than the cells in the remaining regions. Staining is also noted along the surface 
membrane of the cells of the remaining mucosa. 
 
 
Figure 7.8 Immunohistochemical staining of uPAR within the urinary bladder. Intense granular 
staining is noted along the membrane of the luminal cells of the transitional epithelium. Granular 
cytoplasmic staining is noted within the first cell layer of the transitional epithelium and 
inflammatory cells in the urinary bladder wall. 
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prostate and showed variable light staining in the cytoplasm of the connective 
tissue cells of glandular epithelium but most glandular tissue did not stain. 
Epithelial cells lining the prostatic ducts did not stain. Inflammatory cells within 
the connective tissue of the prostate stained positive. Male 2 had a mature 
prostate with some evidence of hyperplasia. Some faint staining of the cytoplasm 
of glandular cells was noted but the majority of the glandular cells did not stain. 
The prostate of male 3 was mature and hyperplastic. Fixation of the tissue was 
not optimal but showed very weak staining of some glandular cells. Male 4 was a 
young dog and the prostate had very little acinar development. Urokinase 
staining was prominent in the regions of developing ducts in the epithelial cells 
lining the ducts. Staining was decreased but still present in comparable cells in 
more differentiated ducts. Staining was also visualized in inflammatory cells 
within the glandular connective tissue (figure 7.9).  Male 5 was a mature dog 
prostate sample with multiple hyperplastic and cystic regions. Epithelium within 
the ducts and the glandular epithelium of the cystic regions showed moderate to 
intense staining. Very weak to no staining was noted in the glandular cells of the 
hyperplastic regions. Male 6 had normal prostate tissue and no staining was 
noted in glands or ducts. Very light staining was noted in the cytoplasm of a few 
foamy prostatic cells. The prostate of Male 7 was hypoplastic or atrophied. 
Prostatic glandular epithelial tissue and apical cytoplasm of the epithelial cells 
within the ducts stained. Inflammatory cells in the connective tissue and vascular 
endothelium stained. Some staining was noted in the cytoplasm of epithelial cells 





Figure 7.9 Immunohistochemical staining of uPA in the prostate of Male 4. Epithelial cells along 
surrounding the duct show staining at the apical membrane and within the cytoplasm.  
7.4.8 Urokinase Receptor and Prostate 
 Most of the prostatic sections did not stain for urokinase receptor staining 
(appendix table 8). Inflammatory cells in the connective tissue stained well in all 
samples, acting as an internal control. Male 4 was intact and granular staining 
was visualized in the epithelial cells of the developing ducts at both the apical 
surface and the cytoplasm. Staining was also noted in the more mature ducts at 
the apical borders of the epithelial cells at the same intensity as the less mature 
ducts. Intense staining was evident in interstitial inflammatory cells (figure 7.10). 
Male 7 was neutered and the prostate appeared hypoplastic or atrophied 
suggesting castration had been performed at a young age or that the gland was 
involuting. Granular staining was noted in the apical region of epithelial cells 
lining primitive or poorly developed ducts. Inflammatory cells in the glandular 




Figure 7.10 Immunohistochemical staining of uPAR in the prostate of Male 4. Intense staining is 
noted along the cell membranes and within the cytoplasm of the epithelial cells lining the 
developing acinar structures. 
7.4.9 Urokinase and Testicle 
 Cytoplasm in the cells in the testicle stained intensely in all samples 
throughout the interstitial cells and the seminiferous tubules, including all phases 
of spermatogonia (figure 7.11 and appendix table 9). 
 7.4.10 Urokinase Receptor and Testicle 
 Testicular cells did not to stain well for urokinase receptor. Very faint 
staining was noted in the cytoplasm of interstitial cells. The seminiferous tubules 
and the contained spermatogonia did not stain. Inflammatory cells in the 
connective tissue still stained (figure 7.12 and appendix table 9) 
7.4.11 Urokinase and Urethra 
 Transitional epithelium within the ureter showed consistent staining along 





Figure 7.11 Immunohistochemical staining uPA in the testicle. Intense staining in noted 





Figure 7.12 Immunohistochemical staining of uPAR in the testicle. Very faint staining of the 
cytoplasm of the interstitial cells is seen.  
 
 
through the mucosa in all dogs evaluated (appendix table 7). This staining was 
similar to the urinary bladder mucosa in those areas which appeared to have 
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increased numbers of cells with vacuolated cytoplasm and was invaginated. In 
other areas of the mucosa, the staining was more luminal and in some places no 
staining. Inflammatory cells in the connective tissue of the urethral wall stained 
well (figure 7.14) There was no difference in the transitional epithelium of the 
prostatic (figure 7.13) and penile urethra of male dogs. 
7.4.12 Urokinase Receptor and Ureter 
 The transitional epithelium of the ureter stained for urokinase receptor on 
the luminal surface of the cells and within the cytoplasm of the cells closest to the 
lumen (appendix table 7). The staining was granular. Inflammatory cells in the 
connective tissue of the urethral wall stained positive (figure 7.16) Cells of the 
transitional epithelium of the prostatic urethra (figure 7.15) stained more intensely 
than the cells of the transitional epithelium of the penile urethra in some sections. 
 
 
Figure 7.13 Immunohistochemical staining of uPA in the prostatic urethra. Staining is noted in the 
cytoplasm of cells in the transitional epithelium in the invaginated section. These cells are also 
more vacuolated than the cells in the remaining regions. Staining is also noted along the surface 





Figure 7.14 Immunohistochemical staining of uPA in the urethra. Staining is noted along the 
entire layer of luminal cells along the membrane and in the cytoplasm. Staining continues 
throughout the cell layers in the mucosa in some regions of the section examined. Cytoplasm of 




Figure 7.15 Immunohistochemical staining of uPAR in the prostatic urethra. 
Light staining is present along the outer membrane of the luminal transitional epithelium and 
within the cytoplasm of some epithelial cells in the upper corner of the invagination. Inflammatory 





Figure 7.16 Immunohistochemical staining of uPAR in the urethra. Intense granular staining is 
noted along the membrane of the luminal cells of the transitional epithelium. Granular cytoplasmic 




Urokinase and urokinase receptor appear to be present in all tissues of 
the urinary tract of the dog. Urokinase receptor appears to be present in most 
tissues except the testicle.  
The kidney specimens evaluated in our study showed staining for 
urokinase in the epithelium of the renal tubules throughout the kidney and 
staining along the epithelial cells of the glomeruli in most specimens. Urokinase 
expression in the kidney is consistent with that reported in the literature for 
people, mice and rats. Immunohistochemistry cannot differentiate whether the 
antigen is present due to synthesis within the cells or because of binding to a 
receptor in or on the cell membrane. However, invitro and tissue studies of cells 
lines from human mesangial and tubule cells show that urokinase is synthesized 
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and secreted by glomerular visceral epithelial cells and kidney tubular epithelial 
cells.9-11 Given these findings in other mammalian species the urokinase in the 
renal tubules and glomeruli of the dog is likely synthesized there also. To verify 
this, cell culture studies would be required to document secretion of urokinase 
into the cell medium. 
Within the kidney urokinase staining was also visualized along the 
transitional epithelium of the renal pelvis. Staining was intense and throughout 
the cytoplasm of all cell layers. Presence of and fibrinolytic activity of urokinase 
has been documented in epithelial cells of the renal calyces.11, 12 Urokinase may 
be produced the transitional epithelial cells. This has been shown to be the case 
in bovine urothelium. 13 To my knowledge this has not been investigated in other 
species. Presence of urokinase in the tubular structures of the urinary tract is 
important to maintain patency of the urinary tract in face of hemorrhage and fibrin 
deposition. 
Urokinase receptor staining in the tissues of the kidney was limited to the 
basement membranes of renal tubular cells. Urokinase receptor staining is not 
noted in normal murine kidney samples. 14 This is consistent with findings from 
people in which urokinase receptor was not noted in the tubules of the kidneys 
from healthy people presenting as donors.15 In another study glomerular cells did 
not stain in healthy kidney samples.16 In the dog kidney studied, uPAR was 
present along the basement membrane. This could indicate that the canine 
kidney does produce uPAR and is different than human kidneys in healthy 
subjects. Many of the dogs in our study did have heartworm disease as evident 
by the identification of microfilaria in glomeruli. This may have resulted in mild 
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interstitial disease and upregulation of uPAR in these dogs. More samples would 
have to be evaluated from known heartworm negative dogs to answer this 
question. Based on this study we can only say that urokinase receptor is present 
in the kidney of dogs. The role of uPAR and sites of production cannot be 
determined without additional studies such as cell culture.  
Transitional epithelium in the renal pelvis showed positive urokinase 
receptor staining along the surface and within cytoplasm of luminal cells in the 
same regions as urokinase staining in the renal pelvis. This may indicate that at 
least some of the urokinase in this tissue is bound to urokinase receptor at the 
cell surface or that urokinase is produced in this tissue. 
The pattern of urokinase staining along the mucosal surfaces of the 
urinary tract was consistent between section and site. The ureter stained most 
intensely along the entire region of transitional epithelium available for 
examination on the slide preparations. Within the urinary bladder and the ureter 
the staining was more variable. These tissues stained but only in some regions. 
The regions more likely to stain were areas which appeared to be invaginated 
and the cytoplasm of the staining cells had increased vacuolization. Areas of the 
mucosa which had decreased staining often stained along the luminal surface 
edge and sometimes into the cytoplasm of the first layer of cells. The significance 
of this finding is unknown. The stained regions may be areas of urokinase 
binding to cells which are damaged or being renewed or these regions may be 
indicative of urokinase producing cells with the transitional epithelium. Bovine 
urothelium has been shown to produce urokinase in culture medium.13 
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Urokinase receptor showed a similar pattern of staining to urokinase. It 
differed in that its appearance was granular and the staining was limited to the 
luminal surface and the cytoplasm of the first one to two layers of cells. It did not 
extend to the inner most layers of the mucosa. This pattern could indicate that 
the urokinase is being produced and secreted by the deeper cells layers and 
then bound to the luminal layers. These layers are rapidly turned over in the 
urinary tract.  
The variability of urokinase expression within the prostate tissue is 
interesting. I do not believe that this series of samples adequately describes the 
presence of urokinase and urokinase receptor in this tissue type, as presence 
seems to depend greatly on stage of development within the prostate gland. It 
has been shown that urokinase production in rats is influenced by hormones.17-19 
In these rats, immunohistochemical evaluation found urokinase to be present in 
scattered cells at the surface of the epithelium facing the lumen of the glandular 
ducts. This staining increased in epithelium after castration suggesting a role for 
urokinase in the involution of the ventral prostate of the rat as well as in the 
normal turnover of prostate epithelium.19 Increased activity of plasminogen 
activators was noted with use of plasminogen activator assays in developing 
prostate tissue which decreased when development was complete.17 This is 
consistent with the role of urokinase and other plasminogen activators in tissue 
remodeling. This is supported by the findings of this study in which expression of 
urokinase and urokinase receptor appeared to be limited to only developing 
ductile tissue. More samples at set developmental stages would be required to 
adequately characterize the presence of urokinase within the prostate of the dog. 
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Urokinase receptor did not stain the majority of prostate sample evaluated. 
Male 4 was intact and staining was visualized in the epithelial cells of the 
developing ducts at both the apical surface and the cytoplasm. Staining was also 
noted in the more mature ducts at the apical borders of the epithelial cells at the 
same intensity as the less mature ducts. Male 7 was neutered but the prostate 
appeared hypoplastic or atrophied suggesting castration had been performed at 
a young age and maybe recently leading to involution. Granular staining was 
noted around primitive or poorly developed ducts in the apical region. Staining 
urokinase and urokinase receptor in the same regions leads to question of 
whether urokinase is produced in these tissues or bound to the cells. It is 
possible, given the abundance of urokinase within the other tissues of the urinary 
tract, that urokinase is truly bound at this site and not produced. Answering this 
question would require cell culture and measurement of products in the culture 
medium. Urokinase and urokinase receptor may contribute to tissue remodeling 
in the prostate of the dog. The importance of uPA and uPAR in development of 
the gland and involution after castration has been shown in rat models of 
prostate development.18, 20, 21 Urokinase and urokinase receptor are known to be 
important in tissue remodeling due to the ability of the uPA-uPAR complex to 
degrade basement membranes in inflammation and neoplasia.22 
Intense staining for uPA was seen in testicle sections. Seminiferous 
tubules and interstial cells all stained in the dog. This has been documented in 
the rhesus monkey and man.23, 24, 25 The role of urokinase in the testicle is 
believed to be in spermatogenesis and sperm motility. It has been suggested that 
infertility in some men may be due decreased levels of urokinase within the 
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testicle.25 The role of urokinase in the dog cannot be determined by 
immunohistochemistry. Urokinase receptor did not stain in the seminiferous 
tubules of the dog. Staining was very weak in the cytoplasm of the interstitial 
cells. Urokinase may be produced in the testicle is produced there and not 
bound. In vitro studies in cell culture would provide further information on exactly 
which cell types produce urokinase. 
The expectation that urokinase would be present in the canine urinary 
tract is extrapolated from evidence of its presence in people. Actual identification 
of urokinase in the canine urinary tract has not been previously performed. Cell 
types which stained positive for urokinase and urokinase receptor in the tissues 
from the dog are consistent with those described in both people, rats, monkeys 
and mice. This lends support to the results of the immunohistochemical staining.  
Currently there are no specific antibodies for canine urokinase. Use of an 
antibody from another species to identify uPA and uPAR poses problems when 
interpreting results. Use of antibodies which were successfully used in our 
immunoprecipitation and SDS PAGE/ Western Blot also helps to validate the use 
of these antibodies in the canine tissues and support the conclusions that uPA an 
uPAR are present in the urinary tract of the healthy dog.     
Selection of an antibody for identification of urokinase in the canine urinary 
tract required consideration of any documentation of cross species reactivity of 
that antibody. Different antigens have greater or less degree of species 
specificity than others. At least two investigations have used a mouse anti-human 
monoclonal antibody from American Diagnostica to successfully detect urokinase 
within bovine urothelium and rat mammary tissue.13, 26 A third investigation used 
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a polyclonal goat antihuman uPA antibody to demonstrate uPA in bovine 
endothelial cells.27 This cross species reactivity would suggest that at least some 
segment of the uPA protein structure is retained across some species and or 
results suggest this includes the dog. 
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Chapter 8 Conclusions 
 
Identification of proteins such as urokinase and urokinase receptor in a 
species without species specific antibodies provides numerous challenges. In 
veterinary medicine we must often rely on antibodies produced for human 
medical research and therefore our findings cannot always be conclusive and we 
are left stating that, as in this case, we have identified urokinase-like and 
urokinase receptor-like proteins and activity in the samples tested.  
Uses of multiple methods of detection which support the finding of each 
test help validate the use of uPA and uPAR antibodies directed against mouse 
and human proteins for detection of the homologous protein in dogs. SDS-
PAGE/Western Blot and immunoprecipitation all demonstrated antibody binding 
with uPA-like and uPAR-like protein at the accepted molecular weight for these 
proteins. Immunohistochemistry showed positive staining in tissues of the urinary 
tract from the dog in cells consistent with descriptions from other mammals 
including people, rats, mice and monkeys. The ELISA assay also detected 
presence of a uPA-like protein in concentrated urine samples. All of these 
immunological techniques were run with the same mouse anti-mouse 
monoclonal antibody from Innovative Research.  
The fluorescence assay and ELISA assay are promising methods to 
evaluate concentration of uPA in urine samples. They require more time and 
work to eliminate variability and improve the results. Whether or not they will 
provide information that may be useful in a clinical setting is not determined since 
recent literature has conflicted as to whether renal disease would result in 
increased or decreased release of uPA into the urine. These assays may be very 
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useful, however, in evaluating tissues in studies on wound healing and cancer 
growth and metastasis. 
This research has resulted in very strong evidence that urokinase and 
urokinase receptor are present in the urinary tract of the healthy dog. The 
























APPENDIX: RAW DATA 
 
Table 1 Clinical Parameters for establishing health of dogs for urine collection 
Group N Case BUN Creatinine Phosphorus Urine Spec Grav PCV 
f 1 80735 12   1.019 44.3 
f 2 79737     47 
f 3 80810 9   1.037 33 
f 4 74708 20 1.2 4.5 1.049 50 
f 5 81588 15 0.7 4.5  45 
f 6 81020 25   1.015 43.8 
f 7 81038 8 0.8 3.2  50 
f 8 81833 20 0.7 4.9 1.038 40 
fs 1 62001 15 0.6 2.6  45.8 
fs 2 81144 9 0.8 4.5 1.027 36.5 
fs 3 81357 13 1 4.1 1.032 49 
fs 4 76045 17 0.9 3.9  45 
fs 5 81337 18 1.3 3.6 1.02 44.7 
fs 6 81375 16 0.9 3.5 1.044 44.6 
fs 7 81414 9 0.7 3.1 1.013 41.3 
fs 8 81441 17 0.9 7.9  36.4 
fs 9 81188 16 0.9 5.1 1.017 37.6 
fs 10 81496 22 0.7 5.1 1.027 49.6 
fs 11 76846 14 1 2.8 1.05 48.3 
fs 12 81517 11 0.8 2.7 1.048 34.6 
fs 13 81528 9 0.3 5 1.008 41.6 
m 1 81252 10   1.011 43.6 
m 2 67922 20 1.1 3.7 1.037 45 
m 3 80982 14   1.038 41 
m 4 81451 16 1.1 4.7 1.049 42 
m 5 81460 11 1 3.8 10.32 45 
m 6 81419 10 0.6 3.4 1.038 44 
m 7 81440 17   1.055 57 
m 8 81482 25 0.9 4.2  40 
m 9 54704 6 0.3 7.7 1.024 29 
m 10 81610 17 0.4 4.1  43 
m 11 81618 18 0.9 4.3 1.057 31 
m 12 81748 15 1 4.7 1.045 51 
m 13 81892 10 0.7 4.2 1.017 55 
m 14 81913 8 1.2 4.8 1.037 49 
m 15 81108 10   1.048 43 
m 16 81962 13 0.4 5.7 1.041 33 
mc 1 78717 17 1 4.1 1.01 46 
mc 2 72533 21 1 4.5 1.028 41 
mc 3 81360 16 0.7 3.1 1.025 44 
mc 4 81380 7 0.4 4 1.012 39 
mc 5 81356 22 1 4.3 1.035 41 
mc 6 78701 20 1.2 4.3  42 
mc 7 81445 14 1 2.6  48 
mc 8 78785 36 0.8 5.3 1.038 52 
mc 9 81494 9 0.9 4.5 1.028 46 
mc 10 81511 21 1.3 6.6 1.012 35 
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mc 11 48505 15 0.5 2.7 1.041 45 
mc 12 81635 7 0.5 2.8 1.029 38 




 f = female intact 
 fs = female spayed 
 m = male intact 
 mc = male castrated 
N = Dog number 
Case – Louisiana State University veterinary Teaching Hospital and Clinic patient 
number 
BUN – blood urea nitrogen mg/dl 
Creatinine – mg/dl 
Phosphorus – mg/dl 
Urine SG – Urine specific gravity 
PCV – Packed cell volume % 
Total protein – g/dl 
 
Table 2 Fluorescence activity assay data 
















M#1 81252 57 50 450 111.1111 28 12 30 0.182055
M#2 67922 234 12.9 400 32.25 18 0 11 0.075423
M#3 80982 103 45 410 109.7561 0 0 39 0.101431
M#4 81451 356 19 150 126.6667 13 10 0 0.059818
M#5 81460 410 13.5 225 60 0 0 0 0
M#6 81419 65 16.2 525 30.85714 0 0 0 0
M#7 81440 87 2 150 13.33333 14 12 3 0.075432
M#8 81482 89 48 350 137.1429 0 0 0 0
M#9 54704 213 6.5 200 32.5 22 25 43 0.234071
M#10 81610 150 4.5 150 30 0 0 0 0
M#11 81618 435 13.5 175 77.14286 0 0 0 0
M#12 81748 466 47 300 156.6667 1 0 0 0.002601
M#13 81892 109 45 300 150 0 0 0 0
M#14 81913 261 42 275 152.7273 25 35 49 0.283485
M#15 81108 514 5.5 225 24.44444 0 0 0 0
M#16 81962 127 11 160 68.75 0 0 0 0
F#1 80735 123 52 450 115.5556 0 0 0 0
F#2 79737 159 11 150 73.33333 0 40 43 0.215865
F#3 80810 176 17 150 113.3333 5 0 0 0.013004
F#4 74708 380 48 755 63.57616 0 12 15 0.070221
F#6 81588 223 10.5 175 60 16 5 5 0.06762
F#7 81020 95 30 275 109.0909 0 0 0 0
F#8 81038 415 49 475 103.1579 0 0 0 0
F#9 81833 393 50 450 111.1111 0 0 0 0
M/N#1 78717 86 56 725 77.24138 0 2 0 0.005202
M/N#2 72533 128 19 140 135.7143 1 0 0 0.002601
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M/N#3 81360 166 41 250 164 41 31 16 0.228869
M/N#4 81380 44 22 150 146.6667 37 33 10 0.208063
M/N#5 81356 213 42 450 93.33333 20 17 2 0.101431
M/N#6 78701 553 20 160 125 0 0 0 0
M/N#7 81445 621 50.5 300 168.3333 122 142 135 1.035112
M/N#8 78785 52 24 160 150 0 0 0 0
M/N#9 81494 213 32.5 175 185.7143 8 12 6 0.06762
M/N#10 81511 98 7.5 150 50 0 0 0 0
M/N#11 48505 134 36 450 80 36 22 34 0.239272
M/N#12 81635 27 29 275 105.4545 6 1 0 0.018205
M/N#13 81688 49 50 550 90.90909 0 0 2 0.005202
F/S#1 62001 192 13.5 175 77.14286 0 0 0 0
F/S#3 81144 218 50 350 142.8571 0 0 0 0
F/S#4 81357 152 21.5 275 78.18182 0 0 0 0
F/S#5 76045 228 4.5 150 30 0 0 0 0
F/S#6 81337 114 44 300 146.6667 0 5 6 0.028609
F/S#7 81375 179 3.5 125 28 0 0 0 0
F/S#8 81414 283 6.5 350 18.57143 0 0 0 0
F/S#9 81441 173 45 450 100 58 74 93 0.585176
F/S#10 81188 138 10.5 200 52.5 19 25 34 0.202861
F/S#11 81496 90 14 150 93.33333 0 0 0 0
F/S#12 76846 468 15.5 175 88.57143 5 6 11 0.057217
F/S#13 81517 427 32.7 675 48.44444 19 47 39 0.273082





 f = female intact 
 fs = female spayed 
 m = male intact 
 mc = male castrated 
Sample = Dog number 
Pt # – Louisiana State University Veterinary Teaching Hospital and Clinic patient 
number 
Creat – Urine creatinine mg/dl 
Fluoro 1, 2 and 3 – Values of Fluorescence readings for each sample corrected 
for background 
uPA concentration fluoro – Concentrations of uPA in each samples as compared 
to standard dilutions of uPA and a global fit standard curve extrapolated from the 








Figure 1 Sample Standard Curve for Fluorescence Data  
 
Table 3 ELISA assay data 










Cr/ml ng/mg Cr/ul 
f 1 80735 1 123 52 450 32.693 0.28292019 0.02300164 23.0016417
f 1 80735 2 123 52 450 . . . . 
f 2 79737 1 159 11 150 . . . . 
f 2 79737 2 159 11 150 . . . . 
f 3 80810 1 176 17 150 22.634 0.19971176 0.01134726 11.3472594
f 3 80810 2 176 17 150 . . . . 
f 4 74708 1 380 48 755 19.4 0.30514583 0.00803015 8.03015351
f 4 74708 2 380 48 755 15.089 0.2373374 0.00624572 6.24572094
f 5 81588 1 223 10.5 175 8.622 0.1437 0.00644395 6.44394619
f 5 81588 2 223 10.5 175 -3.233 -0.0538833 -0.0024163 -2.416293 
f 6 81020 1 95 30 275 35.926 0.32932167 0.03466544 34.6654386
f 6 81020 2 95 30 275 . . . . 
f 7 81038 1 415 49 475 74.009 0.71743418 0.01728757 17.2875707
f 7 81038 2 415 49 475 85.146 0.8253949 0.01988903 19.8890337
f 8 81833 1 393 50 450 65.745 0.591705 0.01505611 15.0561069
f 8 81833 2 393 50 450 68.62 0.61758 0.0157145 15.7145038
fs 1 62001 1 192 13.5 175 35.926 0.46570741 0.02425559 24.2555941
fs 1 62001 2 192 13.5 175 . . . . 
fs 2 81144 1 218 50 350 34.849 0.243943 0.01119005 11.1900459
fs 2 81144 2 218 50 350 37.723 0.264061 0.01211289 12.1128899
fs 3 81357 1 152 21.5 275 8.982 0.11488605 0.00755829 7.55829253
fs 3 81357 2 152 21.5 275 12.215 0.15623837 0.01027884 10.2788403
fs 4 76045 1 228 4.5 150 26.226 0.8742 0.03834211 38.3421053
fs 4 76045 2 228 4.5 150 . . . . 
fs 5 81337 1 114 44 300 . . . . 
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fs 5 81337 2 114 44 300 . . . . 
fs 6 81375 1 179 3.5 125 51.375 1.83482143 0.10250399 102.50399 
fs 6 81375 2 179 3.5 125 . . . . 
fs 7 81414 1 283 6.5 350 27.304 1.47021538 0.05195107 51.9510737
fs 7 81414 2 283 6.5 350 34.13 1.83776923 0.06493884 64.9388421
fs 8 81441 1 173 45 450 39.519 0.39519 0.02284335 22.8433526
fs 8 81441 2 173 45 450 . . . . 
fs 9 81188 1 138 10.5 200 24.789 0.47217143 0.03421532 34.2153209
fs 9 81188 2 138 10.5 200 48.86 0.93066667 0.06743961 67.4396135
fs 10 81496 1 90 14 150 . . . . 
fs 10 81496 2 90 14 150 . . . . 
fs 11 76846 1 468 15.5 175 . . . . 
fs 11 76846 2 468 15.5 175 . . . . 
fs 12 81517 1 427 32.7 675 139.754 2.88483028 0.06756043 67.560428 
fs 12 81517 2 427 32.7 675 142.628 2.94415596 0.06894979 68.9497884
fs 13 81528 1 28 44 400 69.697 0.63360909 0.22628896 226.288961
fs 13 81528 2 28 44 400 65.027 0.59115455 0.21112662 211.126623
m 1 81252 1 57 50 450 10.419 0.093771 0.01645105 16.4510526
m 1 81252 2 57 50 450 20.837 0.187533 0.03290053 32.9005263
m 2 67922 1 234 12.9 400 67.542 2.09432558 0.08950109 89.5010932
m 2 67922 2 234 12.9 400 70.416 2.18344186 0.09330948 93.3094812
m 3 80982 1 103 45 410 20.119 0.18330644 0.01779674 17.7967422
m 3 80982 2 103 45 410 26.226 0.238948 0.02319883 23.198835 
m 4 81451 1 356 19 150 18.682 0.14748947 0.00414296 4.14296274
m 4 81451 2 356 19 150 . . . . 
m 5 81460 1 410 13.5 225 20.837 0.34728333 0.00847033 8.4703252 
m 5 81460 2 410 13.5 225 26.586 0.4431 0.01080732 10.8073171
m 6 81419 1 65 16.2 525 18.682 0.60543519 0.09314387 93.1438746
m 6 81419 2 65 16.2 525 77.601 2.51484722 0.38689957 386.899573
m 7 81440 1 87 2 150 26.226 1.96695 0.22608621 226.086207
m 7 81440 2 87 2 150 . . . . 
m 8 81482 1 89 48 350 . . . . 
m 8 81482 2 89 48 350 . . . . 
m 9 54704 1 213 6.5 200 . . . . 
m 9 54704 2 213 6.5 200 . . . . 
m 10 81610 1 150 4.5 150 16.526 0.55086667 0.03672444 36.7244444
m 10 81610 2 150 4.5 150 . . . . 
m 11 81618 1 435 13.5 175 68.979 0.89417222 0.02055568 20.5556833
m 11 81618 2 435 13.5 175 . . . . 
m 12 81748 1 466 47 300 26.945 0.17198936 0.00369076 3.69075883
m 12 81748 2 466 47 300 29.46 0.18804255 0.00403525 4.03524792
m 13 81892 1 109 45 300 12.215 0.08143333 0.00747095 7.47094801
m 13 81892 2 109 45 300 43.471 0.28980667 0.02658777 26.5877676
m 14 81913 1 261 42 275 . . . . 
m 14 81913 2 261 42 275 . . . . 
m 15 81108 1 514 5.5 225 61.705 2.52429545 0.04911081 49.1108065
m 15 81108 2 514 5.5 225 51.375 2.10170455 0.04088919 40.8891935
m 16 81962 1 127 11 160 . . . . 
m 16 81962 2 127 11 160 . . . . 
mc 1 78717 1 86 56 725 14.011 0.18139241 0.02109214 21.0921408
mc 1 78717 2 86 56 725 8.622 0.11162411 0.01297955 12.9795473
 131
mc 2 72533 1 128 19 140 1.437 0.01058842 0.00082722 0.82722039
mc 2 72533 2 128 19 140 -2.874 -0.0211768 -0.0016544 -1.6544408 
mc 3 81360 1 166 41 250 59.279 0.36145732 0.02177454 21.7745372
mc 3 81360 2 166 41 250 66.464 0.40526829 0.02441375 24.4137526
mc 4 81380 1 44 22 150 . . . . 
mc 4 81380 2 44 22 150 . . . . 
mc 5 81356 1 213 42 450 . . . . 
mc 5 81356 2 213 42 450 . . . . 
mc 6 78701 1 553 20 160 93.409 0.747272 0.01351306 13.5130561
mc 6 78701 2 553 20 160 . . . . 
mc 7 81445 1 621 50.5 300 66.823 0.39696832 0.0063924 6.39240446
mc 7 81445 2 621 50.5 300 86.583 0.51435446 0.00828268 8.28268044
mc 8 78785 1 52 24 160 . . . . 
mc 8 78785 2 52 24 160 . . . . 
mc 9 81494 1 213 32.5 175 . . . . 
mc 9 81494 2 213 32.5 175 . . . . 
mc 10 81511 1 98 7.5 150 36.645 0.7329 0.07478571 74.7857143
mc 10 81511 2 98 7.5 150 . . . . 
mc 11 48505 1 134 36 450 54.608 0.6826 0.0509403 50.9402985
mc 11 48505 2 134 36 450 63.949 0.7993625 0.05965392 59.6539179
mc 12 81635 1 27 29 275 10.419 0.09880086 0.03659291 36.5929119
mc 12 81635 2 27 29 275 10.778 0.10220517 0.03785377 37.8537676
mc 13 81688 1 49 50 550 38.441 0.422851 0.08629612 86.2961224




 f = female intact 
 fs = female spayed 
 m = male intact 
 mc = male castrated 
N = Dog number  
Case – Louisiana State University veterinary Teaching Hospital and Clinic patient 
number 
Sample – denotes duplicate wells for samples, 1 or 2 
Cr mg/dl – Creatinine value for each urine sample 
Start Vol ml – Initial volume in milliliters of urine collected prior to filtration 
End Vol ul – Final volume of urine in microliters after filtration. 
uPA ng/ml – Concentration of uPA in each well in ng/ml 
volcorr – concentration factor for each urine sample based on  
start volume µl / end volume µl 
ng/mg Cr/ml – (concentration of uPA in each sample / creatinine mg/dl)  

























Figure 2 Standard Curve for ELISA assay 
 
Table 4 Immunohistochemistry results for uPA and uPAR in Kidney Sections 
 




Staining in all tubular 
epithelial cells, proximal 
smooth muscle in 
arteries, occasional 
plasma cell 
Staining in proximal and 
medullary tubules along 
basement membrane, 
along basilar edge of 
tubular epithelial cells, 
macrophages 
Male #2 Good staining in all 
tubular epithelium, slight 
staining in glomeruli, 
sectional staining in 
transitional epithelium 
Granular staining along 
the basement membrane, 
increased in medullary 
tubules. Intense in LOH 
and some collecting 
ducts. Staining 
throughout transitional 
epithelium on surface 
and in cytoplasm 
Male #3 Good staining in tubular 
epithelial cells, cortical 
and medullary. Positive 
staining along transitional 
epithelium. Some 
staining in glomeruli. 
Slight staining on surface 
of transitional epithelium. 
Light, granular staining 
along the basement 
membrane of all tubules. 
Small amt staining on 
apical membrane of the 
ureter. Glomeruli 
negative 



















tubular epithelial cells. 
Diffuse pale staining of 
the glomeruli. Faint 




staining along the 
basement membrane of 
the medullary tubules 
and proximal tubules. 
Some staining n apical 
membrane of the 
proximal tubules 
Male #5 Diffuse cytoplasmic 
staining in the tubular 
cells. Glomeruli negative. 
Positive staining in 
plasma cells 
Faint staining along 
basement membranes in 
the tubules, some on 
apical membrane as well. 
Faint cytoplasmic 
staining in proximal 
tubules 
Male #6 Diffuse staining in the 
tubules. Medullary ray 
tubules staining more 
intently than proximal 
convoluted tubules. 
Transitional epithelium 
staining in sections along 
the surface. 
Granular basement 
membrane staining in 
proximal and medullary 
tubules.  
Male #7 Intense staining in the 
medullary and cortical 
tubules. More intense in 
medullary. Good 
variability in staining of 
the transitional 
epithelium. Slight staining 
in glomeruli 
Very slight staining of 
basement membranes of 
cortical tubules. Nice 
staining in medullary 
tubules. Negative 
glomeruli. Staining of 
transitional epithelium on 
surface and within 
cytoplasm of cells 
Female #1 Good staining of all 
tubular epithelial cells. A 
few medullary ray tubules 
staining brighter than 
proximal tubules. 
Transitional epithelium 
staining in alternating 
regions. 
Faint granular staining 
along basement 
membrane. Most 
prominent in medullar 
tubules and loops of 
henle and collecting 
ducts. Transitional 
epithelium showed 
staining along the 
surface. 
Female #2   
Female #3 Transitional staining 
inconsistently. Maybe 
positive in recesses of 
Very faint granular 
staining along tubular 
basement membrane. 
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pelvis and negative in the 
crest. Diffuse proximal 
and medullary epithelium. 
Faint glomerular staining. 
Diffuse interstitial staining 
in medulla 
Membrane associated 
surface staining on 
transitional epithelium   
Female #4 Good staining in tubular 
epithelial cells. Collecting 
ducts staining better than 
loop of henle. Glomeruli 
negative. 
Granular staining along 
the basement membrane 
of tubular cells. 
 
Key: 
Males 1,2,3,4 and 5 – intact males 
Males 6 and 7 – castrated males 
Females – intact females  
 
Table 5 Immunohistochemistry Results for uPA and uPAR in Ureter Sections 
Sample Urokinase Urokinase Receptor 
Male #1 Uniform positive staining 
of transitional epithelial 
cells on the surface and 
in the cytoplasm to the 
basal cell layers. 
Inflammatory cells 
stained positive 
Small amount of granular 
staining on the surface of 
the transitional cells and 
in the cytoplasm of the 
cells within the luminal 
region. Inflammatory cells 
stained positive 
Male #2   
Male #3 Uniform positive staining 
of transitional epithelial 
cells on the surface and 
in the cytoplasm to the 
basal cell layers. 
Inflammatory cells 
stained positive 
Mucosa not present on 
sample 
Male #4 Uniform positive staining 
of transitional epithelial 
cells on the surface and 
in the cytoplasm to the 
basal cell layers.  
Nice grainy staining all 
along the surface of the 
transitional epithelium 
and into the cytoplasm of 
the first 2 cell layers 
Male #5 Uniform positive staining 
of transitional epithelial 
cells on the surface and 
in the cytoplasm to the 
basal cell layers. 
Inflammatory cells 
stained positive 
Very slight granular 
staining of the cytoplasm 
of the superficial cell 




Male #6 Uniform positive staining Small amount of granular 
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of transitional epithelial 
cells on the surface and 
in the cytoplasm to the 
basal cell layers. 
staining on the surface of 
the transitional cells and 
in the cytoplasm of the 
cells within the luminal 
region. Inflammatory cells 
stained positive 
Male #7 Uniform positive staining 
of transitional epithelial 
cells on the surface and 
in the cytoplasm to the 
basal cell layers. 
Very slight granular 
staining of the cytoplasm 
of the superficial cell 




Female #1   
Female #2   
Female #3   
Female #4 Uniform positive staining 
of transitional epithelial 
cells on the surface and 
in the cytoplasm to the 
basal cell layers. 
Very slight granular 
staining of the cytoplasm 
of the superficial cell 




Males 1,2,3,4 and 5 – intact males 
Males 6 and 7 – castrated males 
Females – intact females  
 
Table 6 Immunohistochemistry Results for uPA and uPAR in Urinary Bladder 
Sample Urokinase Urokinase Receptor 
Male #1 Weak staining on the 
surface of transitional 
epithelium. Resident 
inflammatory cells and 
muscle stained positive. 
Vascular endothelium 
stained weakly positive 
Very weak cytoplasmic 
staining in invaginations 
of transitional epithelium. 
Granular staining on 
surface of transitional 
epithelium. Inflammatory 





stained intensely along 
the superficial surface 








Good staining along 
sections of the 
transitional epithelium. 
Staining is throughout all 
Some staining on the 
apical surface of 
transitional epithelium. 
Some staining in 
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cells of the epithelium. 
Staining is variable in 
sections 
cytoplasm through outer 
layer of transitional 
epithelium 
Male #4 Good staining along 
sections of the 
transitional epithelium. 
Vacuolated cytoplasm in 
invaginated regions 
tended to stain 
throughout the cell 
layers. Surface staining 
was positive on 
remaining transitional 
epithelium.  
Granular staining on the 
surface and cytoplasmic 
staining for 1 to 2 cell 
layers within the 
transitional epithelium. 
Male #5 Basal layer of transitional 
epithelium stained 
positive. The overlying 
mucosa is missing from 
the sample. Smooth 
muscle is staining well 
No mucosa to evaluate 
Male #6 No mucosa to evaluate Granular staining on the 
surface and cytoplasmic 
staining for 1 to 2 cell 
layers within the 
transitional epithelium. 
Male #7 No mucosa to evaluate No mucosa to evaluate 
Female #1 Good staining along 
bladder mucosa again in 
variable sections. 
Staining is apical and 
cytoplasm stains better in 
invaginations where cell 
cytoplasm is vacuolated. 
Granular staining on the 
surface of the transitional 
epithelium. 
Female #2 No mucosa to evaluate No mucosa to evaluate 
Female #3 Good staining along 
bladder mucosa in 
variable sections. 
Staining is apical and 
cytoplasm stains better in 
invaginations where cell 
cytoplasm is vacuolated. 
Occasional inflammatory 
cell staining positive 
Granular staining on the 
surface of the transitional 
epithelium. Granularity 
noted around vacuole or 
cell membranes at the 






consistently stained well 
on the surface and within 
the cytoplasm. 
No mucosa to evaluate 
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Occasional regions 
without staining. Positive 
staining in inflammatory 




Males 1,2,3,4 and 5 – intact males 
Males 6 and 7 – castrated males 
Females – intact females  
 
Table 7 Immunohistochemistry Results for uPA and uPAR in Urethra 




Positive staining on the 
surface of the transitional 
epithelium, better in 
crypts and invaginations. 
Prostatic epithelial cells 
near the ureter stain well. 
Concentration of granular 
staining in the superficial 
surface and cytoplasm of 
cells of the transitional 
epithelium. 
Male #2 Poor sample, mucosa 
sloughed 
Poor sample, mucosa 
sloughed 
Male #3 Very intense cytoplasmic 
staining along sections of 
the transitional epithelium 
to sections with no 
staining except for along 
the luminal surface of the 
cells. 
 
Male #4 Very intense cytoplasmic 
staining along sections of 
the transitional epithelium 
to sections with no 
staining except for along 
the luminal surface of the 
cells. Positive staining of 
inflammatory cells, 
vascular endothelial cells 
and some fibroblasts 
Concentration of granular 
staining in the superficial 
cells of the transitional 
epithelium. 
Male #5 Diffuse staining of the 
transitional epithelium 
from the surface 
throughout the cytoplasm 
of the entire layer. 
Intense granular staining 
in the superficial cells of 
the transitional 
epithelium, extending into 
the cytoplasm of the 
luminal cell layers. 
Male #6 Diffuse light staining of 
the transitional epithelium 
from the surface 
Slight granular staining in 
the superficial cells of the 
transitional epithelium, 
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throughout the cytoplasm 
of the entire layer. 
extending into the 
cytoplasm of the luminal 
cell layers. Some 
inflammatory cells 
staining positive 
Male #7 Very intense cytoplasmic 
staining along sections of 
the transitional epithelium 
to one section with no 
staining except for along 
the luminal surface of the 
cells. 
Moderate granular 
staining in the superficial 
cells of the prostatic 
urethral transitional 
epithelium, extending into 
the cytoplasm of the 
luminal cell layers. 
Inflammatory cells 
staining intensely 
positive. Penile urethra 
showed granular staining 
along the surface of the 
transitional epithelium but 
not within the cytoplasm 
Female #1 Muscle and endothelial 
cells stained well,  no 
lumen in the tissue 
sample 
 
Female #2 Good staining of the 
transitional epithelium on 
surface and within the 
cytoplasm. Most regions 
are stained with 
occasional areas 
unstained through the 
cytoplasm. Smoot 
muscle, skeletal muscle, 
fibroblasts and vascular 
endothelial cells are 
staining. 
Concentration of granular 
staining in the superficial 
surface and cytoplasm of 
cells of the transitional 
epithelium. 
Female #3 No lumen in section No lumen in section 
Female #4 Surface and cytoplasmic 
staining along sections of 
the transitional epithelium 
to one section with no 
staining except for along 





Males 1,2,3,4 and 5 – intact males 
Males 6 and 7 – castrated males 
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Females – intact females  
 
Table 8 Immunohistochemistry Results for uPA and uPAR in Prostate 




Variable and light 
staining of the glandular 
epithelium, most of the 
glandular tissue is not 
staining. Light to 
intermediate staining of 
the muscle. Ducts are not 
staining 
No staining in the 
glandular epithelium. 
Slight staining in the 
ductular epithelium which 
may be transitional 





Glandular cells are 
negative. 
Glandular cells are 
negative. Positive 












Not much acinar 
development. Very 
positive staining in 
developing ducts. 
Staining still present but 
slightly less intense in 
more differentiated ducts. 
Positive staining of 
inflammatory cells, 
smooth muscle cells and 
vascular endothelium. 
Prostatic urothelium 
stained in sections, more 
prominent in the folds.  
Not much acinar 
development. Granular 
staining of the epithelial 
cells of the developing 
ducts and more 
differentiated ducts, 
apical and cytoplasmic. 
Intensity of the staining 
appeared equal. Prostatic 
urothelium showed 
granular staining along 
the surface with some 
cytoplasmic staining in 






hyperplasia and atrophy 
Prostatic ducts are 
staining well. Very weak 
to no staining of the 
glandular epithelium. 
Increased staining of the 
cystic glandular 
epithelium. Positive 





No staining of glands or 
ducts. 
No staining on glands or 
ducts. Inflammatory cells 
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Mature are staining positive 
Male #7 
 
Hypoplastic or atrophied 
Positive staining of 
prostatic epithelial tissue 
and ducts, concentrated 
in the apical cytoplasm. 
Positive staining of 
inflammatory cells, 
vascular endothelial cells 
and transitional 
epithelium (in varied 
sections) 
Small amount of positive 
staining around primitive 
or poorly developed 
ducts. Small amount of 
staining on prostatic 
urothelium. Inflammatory 




Males 1,2,3,4 and 5 – intact males 
Males 6 and 7 – castrated males 
 
Table 9 Immunohistochemistry Results for uPA and uPAR in Testicle 
Sample Urokinase Urokinase Receptor 
Male #1 Good staining in 
seminiferous tubules and 
interstitial cells 
Small amount of granular 
cytoplasmic staining in 
some interstitial cells and 
faint staining in 
contractile myoid cells. 
Seminiferous tubules 
negative 
Male #2 Good staining in 
seminiferous tubules and 
interstitial cells. Faint 
staining in vessel walls. 
Small amount of granular 
cytoplasmic staining in 
some interstitial cells and 
faint staining in 
contractile myoid cells. 
Seminiferous tubules 
negative 
Male #3 Good staining in 
seminiferous tubules and 
interstitial cells. Staining 
not as intense 
Small amount of granular 
cytoplasmic staining in 
some interstitial cells and 
faint staining in 
contractile myoid cells. 
Seminiferous tubules 
negative 
Male #4 Good staining in 
seminiferous tubules and 
interstitial cells. Faint 
staining in vessel walls. 
Tunic present and not 
staining 
Questionable staining in 
interstitial cells. 
Male #5 Intense staining in 
interstitial cells (leydig 
Very mild staining in 
interstitial cells. 
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cells). Staining in 
seminiferous tubules, 
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